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Bacillus Calmette-Guerin (BCG) is the first line therapy for bladder cancer
patients with non-invasive disease. However, roughly 40% of patients exhibit no
response, tumor recurrence or tumor progression following BCG treatment. Type
I interferon (IFN-I) has potent anti-tumor effects against urothelial carcinoma
(UC) and may be an alternative treatment option for patients who do not respond
to BCG standard of care. However, the mechanisms that mediate the IFN-Istimulated immune responses against UC are not fully elucidated. Herein, we
evaluated the anti-tumor mechanisms of IFN-I in UC by use of adenoviral
interferon-α (Ad-IFNα/Syn3) in human patients, and poly(I:C) or lentiviral IFN
(LV-IFN) in mice. To this end, I evaluated the IFN-I enhanced immune response
by observing increases in expression of immune cell and checkpoint markers in
tumors pre- and post- IFN-I treatment. I also characterized the tumor-immune
landscape, identified important antitumor effector cells, and described the
pathways elicited to recruit the immune response. I found that IFN-I increased
the intratumoral levels of Ly6G cells, CD8 T cells, and NK cells, and that the antitumor benefit of IFN-I was dependent on IL-6 signaling and multiple immune cell
types. I sought to establish therapeutic synergy between IFN-I therapy and PD-1
pathway checkpoint inhibition, and found combination therapy increases survival
but is not wholly synergistic, and has additional effect in increasing the immune
infiltrate, angiogenesis, and enriching gene signatures of metabolism,
extracellular matrix organization, and MAPK/AKT signaling. Altogether, these
studies highlight the importance of targeting multiple aspects of the immune
response against tumors, and provide a preclinical conceptual example for using
type I IFN activation to increase the therapeutic benefit of PD-1 blockade for
bladder cancer patients.
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Chapter 1: Introduction
The term “cancer” was first described by Hippocrates in the late centuries Before
Common Era, but incidences of cancerous lesions have been documented back
to the Ancient Egyptians. Hailing to the treatment practices of those archaic
times, surgical intervention and removal of tumors has been the ultimate method
of therapy for cancer since 1500 B.C.E. (1). The surgery itself could be
dramatically aggressive, resulting in loss of life, low life expectancy, and low
quality of life, if preserved. Not until the early 20th century did other treatment
modalities such as radiation and hormone therapy begin to enter the medical
field, with indications for the treatment of cancers, particularly for tumors
incapable of being safely resected by surgery. The premise of chemotherapy
was introduced by coincidence during World War II, a by-product of defense
research to protect soldiers against mustard gas. Since its discovery,
chemotherapy has been catapulted into the front line of cancer treatments;
agents which first began as general DNA damagers have evolved into pathwayand gene-specific targeted drugs that can be used alone, in combination with
other chemotherapy agents, or used in an adjuvant capacity in combination with
other therapy modalities. The most recent addition to the arsenal of cancer
therapeutics has been the rapidly expanding field of immunotherapy. With the
goal of capitalizing on the body’s own defense system, immunotherapy has been
highlighted as the future of cancer therapy, meant to succeed where most other
modalities have failed in treatment and prevention of recurrence. In the following
chapter, I aim to provide an overview of the current field of bladder cancer and its
diagnosis and treatment, our immune system and how it recognizes and respond
1

to tumors, with attention paid to mechanisms of tumor-immune suppression, and
finally a discussion on the immunotherapies used to overcome tumorimmunosuppression and treat cancer, focusing on the current status of therapies
in all tumors and specifically in bladder cancer.

1.1: Bladder Cancer

Bladder cancer is the second most widely prevalent cancer type of the
genitourinary malignancies, ranking as the tenth most common malignant
disease worldwide (2). Indeed, 80,470 new cases of bladder cancer and 17,670
estimated deaths attributed to bladder cancer were predicted to occur in the U.S.
in 2019 (3), making it the fourth most common cancer type in men and the twelfth
most common type in females. These estimated incidence and death rates have
increased by 4.4% and 7.3%, respectively, since 2016. Bladder cancer affects
men more frequently than women at a ratio of about 3:1, and incidences increase
with age (2). While genetic predisposition to bladder cancer and other
environmental factors related to diet and occupational exposure to chemical and
water contaminants have shown to be linked to bladder cancer diagnoses (4),
cigarette smoking is the primary risk factor for bladder cancer. Unsurprisingly
epidemiologically, regions where smoking rates are highest have the highest
rates of bladder cancer occurrence.
Most patients are initially diagnosed due to observance of blood in their
urine (hematuria)(5), subsequently confirming the presence of suspected
cancerous lesions by cystoscopy, biopsy, and histopathology. As with most
cancer types, prognosis for bladder cancer depends on the stage and
2

histopathology of the disease. Early staged, minimally-invasive tumors generally
present with good prognosis following the standard of care of tumor resection,
Bacillus Calmette-Guerin (BCG) therapy, and lifelong monitoring (6); patients
with late staged, advanced and potentially metastatic disease have little
treatment options as alternative to aggressive chemotherapy and cystectomy, or
surgical removal of the bladder (7). Despite having a good prognosis, patients
still have high rates of disease recurrence and even progression, making bladder
cancer one of the most expensive of all cancer types due to the constant
surveillance and need for reception procedures. For the more aggressive and
muscle-invasive cancers, radical cystectomy, including prostatectomy in men and
hysterectomy in women in addition to bladder removal, is the gold-standard of
therapy. These procedures result in severely impaired quality of life and an
abysmal 10-year survival rate of <34% when disease involves the surrounding
lymph nodes (8). With a fairly stable bladder cancer incidence due to the lasting
effects of global tobacco usage, and the potential of costly life-long monitoring
and lowered quality of life, there is great interest in development of effective
alternative treatment options to improve the care and survival of bladder cancer
patients.
This section aims to provide a discussion of key differences in bladder
cancer phenotypes, Muscle-Invasive bladder cancer (MIBC) and Non-muscle
Invasive bladder cancer (NMIBC) with a focus on NMIBC, and provide a
summary of the current treatment practices and the utility of biomarkers in early
detection and therapy response.
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1.1.1: Defining the Characteristics of Muscle-Invasive vs. Non-Muscle Invasive
Bladder Cancer Phenotypes

Pathophysiology. Most incidences (about 90%) of bladder cancer are classified
as urothelial carcinomas, and originate from the epithelial cells lining of the
bladder called the urothelium (5). Tumors differ greatly in their histology owing to
their diverse cells of origin or to divergence of cell clones (clonality), which results
in multifocal disease within the standard two-pathway development model of
bladder cancer (papillary, non-invasive lesions or non-papillary, invasive lesions).
Bladder cancer is staged according to the classical Tumor, Node, Metastasis
(TNM) system in which minimally invasive tumors (stages Tis, Ta, and T1)
represent tumors that have remained on the urothelial mucosal surface,
potentially beginning to invade the submucosal lamina propria, or carcinoma in
situ (CIS) (Figure 1). These tumors may also characteristically project out into
the bladder lumen, becoming papillary in nature. Tumors can additionally be
classified as low-grade or high-grade depending on their invasive status into the
lamina propria and muscularis propria. Stage T2, T3, and T4 tumors have
invaded past the first two tissue layers (urothelium and lamina propria) into the
muscular bladder wall and beyond. Early staged tumors (Tis-T1/T2) are typically
classified as non-muscle invasive bladder cancers (NMIBC), and late stage
tumors (T2-T4) are usually appropriately named muscle-invasive bladder cancers
(MIBC) (5, 9). Approximately 75% of new diagnoses of bladder cancer are
NMIBC, and the other 25% of cases are MIBC or metastatic disease (4). About
15-40% of high-grade Ta staged NMIBC tumors, and 30-50% of high-grade T1
staged NMIBC tumors progress to highly invasive disease; however only about
4

20% of initially diagnoses NMIBC patients progress to MIBC with the potential for
metastasis (10). Urothelial carcinomas can also be classified by variant

Figure 1: Stages, grades, and subtypes of bladder cancer. Staging of bladder
cancer according to the TMN system is shown according to the tissue layer of the
tumor invasion. Non-muscle invasive (NMIBC) tumors are the least tissue
invasive tumors, typically papillary in nature and have lower stages (Tis-T1/T2)
and lower graded disease. Muscle-invasive (MIBC) tumors are more aggressive
with higher stages (T2-T4) and higher grades, including invasion past the bladder
muscular wall and into fat and the bloodstream. Grading schemes at the bottom
of the figure reflect World Health Organization (WHO) and International Society
of Urological Pathology (ISUP) disease stratification classifications. PUNLMP,
papillary urothelial malignancy of low malignant potential. This figure was taken
with permission from Sanli, O, Dobruch J, Knowles MA, Burger M, Alemozaffar
M, Nielsen ME, Lotan Y. 2017. Bladder Cancer. Nat Rev Dis Primers (5). License
number 4580430584829.
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histologies including micropapillary, sarcomatoid, squamous, and glandular
differentiation (11); many of these subtypes are aggressive and thus important to
identify in order to avoid misdiagnoses and inappropriate treatment regimes.

Molecular Characteristics. In addition to the TNM classification and invasion
status, bladder tumors can be subtyped by their molecular landscape and
characteristics. In humans and also in mouse models of NMIBC, precursors to
tumors present as hyperplastic lesions where the two most common genetic
alternations found are loss of heterozygosity of chromosome 9, particularly 9q,
and mutations in FGFR3 (12, 13). The deleted areas on chromosome 9
encompass loci for multiple tumor suppressors including CDKN2A, TSC1, and
PTCH1, and are often found deleted in other tumor types (14, 15). FGFR3
activating mutations can trigger activating mutations in PIK3CA and downstream
cell cycle regulatory pathways such as RAS/MAPK signaling, resulting in
increased cell growth and division (15, 16). Whole exome-sequencing of NMIBCs
revealed high frequencies of inactivating mutations in chromatin-modifying
proteins KDM6A, ARID1A, CREBBP, and EP300, present at significantly higher
levels than in other cancer types, signifying a key role for epigenetic regulation in
the development of these tumors (17-19). In contrast to NMIBC, flat dysplastic
lesions or CIS are precursors to MIBC tumors, with generation of MIBCs in
humans and mouse models requiring the inactivation of tumor suppressor genes
Trp53, Rb1, and Pten. These alterations affect cell cycle regulation, genetic
instability and immortality, and regulation of the PI3K/AKT/mTOR pathway (20),
ultimately resulting in increased disease aggressiveness, invasion, and worse
clinical outcomes. In addition to the difference in overall patterns of mutated
6

genes in these two major tumor groups, there is also a significant difference in
their mutational burden. According to exome sequencing studies, NMIBCs have
showed an average of 169-195 mutations, less than two-thirds of 302 mutations
found in MIBCs (17, 18).

Molecular Subtyping. Molecular subtyping of bladder cancer goes deeper than
just characteristics identifying NMIBC and MIBC. As briefly touched on above,
urothelial carcinoma can have differing cells of origin, generating heterogeneous
tumors with varying clinical outcome suggesting there can be subtyping within
subtypes. Transcriptional profiling has provided the best subtyping definitions,
though to date, the major studies performed use different nomenclatures and so
bioinformatics tools have been enlisted to find alignment and overlap of these
profiles (Figure 2). The initial profiling study performed by Lund encompasses
tumors of all grades and stages (NMIBC and MIBC) and defined the following
five subtypes: urobasal A, genomically unstable, (immune) infiltrated, squamous
cell carcinoma-like, and urobasal B (21). Low-grade Ta tumors were classified as
urobasal A, consisting of high levels of markers of urothelial differentiation, cell
adhesion, early cell cycle, and FGFR3-related genes. Stage T1 and high-grade
tumors contained more genomically unstable and infiltrated tumors, classified by
late cell cycle gene expression and markers of urothelial differential, or high
levels of immune cell and stromal markers, respectively. These higher-staged
NMIBC tumors showed more overlap with subtypes of MIBC, which other
independent transcriptional analyses have segregated into two major tumor
groups: “luminal” and “basal” (18, 22, 23). The luminal and basal clusters are
identified by mutually exclusive expression of differentiation markers that were
7

Figure 2: Molecular subtyping of bladder cancer. Several subtypes of NMIBC
and MIBC have been defined based on transcriptional characteristics. a)
UROMOL classification scheme of NMIBC into three class subtypes: Class 1 is
characterized by high expression of early cell cycle and uroplakin genes, which
are involved in urothelial differentiation; Class 2 expresses late cell cycle genes
and shows increases in keratins as well as uroplakins; Class 3 tumors show high
expression of keratins, a sign of undifferentiated (basal) cells, and high levels of
long non-coding RNAs. b) Characterization of bladder cancer subtypes defined
by the University of North Carolina (UNC), MD Anderson Cancer Center (MDA),
The Cancer Genome Atlas (TCGA), and Lund University (Lund) projects. UNC,
MDA, and TCGA included MIBC alone; Lund included both NMIBC and MIBC.
Key markers and therapeutic targets are shown aligning to Lund nomenclature.
This figure was taken with permission from Sanli, O, Dobruch J, Knowles
MA, Burger M, Alemozaffar M, Nielsen ME, Lotan Y. 2017. Bladder Cancer. Nat
Rev Dis Primers (5). License number 4580430584829.
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similar to the intrinsic basal and luminal subtypes of breast cancer (24). MIBC
luminal tumors often display papillary morphology and express markers of
urothelial differentiation such as KRT20, uroplakins, E-cadherin, early cell cycle
genes, and FGFR3. Basal tumor markers reflect their cells of origin in the basal
layer of the bladder, expressing CD44, KRT5, KRT14, markers of EMT, with
some showing low expression of the claudin gene family or squamous
differentiation markers (25). Data from studies performed by UNC, MD Anderson,
and TCGA show that their MIBC clusters overlap with the Lund study’s subtyping
nomenclature of unstable and infiltrated tumors (mostly luminal MIBC), and the
more basal-like groups of urobasal B and squamous cell carcinoma-like (basal
MIBC) (21).
Of the major currently published transcriptional studies, the UROMOL
study focused solely on NMIBC, transcriptional profiling 460 patients with either
low-grade or high-grade Ta, T1 and CIS tumors (26). Comparing their
nomenclature to the original Lund findings, UROMOL Class 1 tumors were very
similar to urobasal A tumors. Consisting of mostly Ta tumors, patients who were
Class 1 showed the best prognosis of all groups. Class 2 contained more highgrade and T1 tumors, more likely to be at risk for recurrence and progression to
MIBC, and aligned most commonly with genomically unstable and infiltrated Lund
profiles (21). It is thought that Class 2 tumors, may represent tumors of origin for
luminal-like MIBC tumors that retain more markers of urothelial differentiation,
based on their characteristic expression of late cell cycle, EMT, and stem-cell
related genes (5). Class 3 tumors had both common gene signatures like FGFR3
of the urobasal A subtype, but also displayed a basal expression pattern similar
to basal MIBCs including expression of KRT5+, KRT14+, and CD44+ (26).
9

Some researchers in the field believe that molecular subtyping of bladder
cancer is at the forefront in the future of disease diagnostics and treatment
planning, predicting that the use of transcriptional profiling will overtake the
traditional reliance on pathology for bladder cancer diagnosis. However, despite
the broader categories of luminal and basal and even more defined categories
like infiltrated and genomically unstable, within each subtype are more specific
tumors types with actionable therapeutic targets, suggesting that future
dependence on molecular classifiers for cancer diagnosis could be a journey
down the rabbit hole. This prospect it a heavily debated topic among the field,
and for the immediate future, efforts are aimed at combining conventional
histopathology, immunohistochemistry, and molecular classification to subtype
bladder cancer diseases and assign therapy (27-30).
In summary, bladder cancer is broadly assigned to a two-pathway system:
non-muscle invasive (NMIBC) or muscle-invasive (MIBC). These two
classifications differ in their stage and grade, as well as their molecular
landscapes and molecular subtypes. These characteristics influence disease
pathology, progression, and prognosis. NMIBCs tend to be papillary, earlier
staged, lower grade, and minimally invasive, characterized by FGFR3 mutations
and higher expression of urothelial differentiation markers, but overall lower
mutational burden. MIBC tumors by comparison are more dysplastic, aggressive,
higher staged, and potentially metastatic. They are characterized by TP53, RB1,
PTEN, and PI3K/AKT/mTOR pathway mutations, have higher mutational loads,
and can be broadly molecularly subtyped into luminal and basal MIBC. The
differences in these two urothelial tumor classifications lead to significant
variation in clinical implications, as well as treatment and disease management.
10

In the future, there needs to be a consensus on nomenclature and characteristics
of bladder cancer subtypes to aid in standardization of patient diagnoses and
development of comprehensive treatments (31). The studies described in the
subsequent chapters will be focused on NMIBC disease.

1.1.2: Standard Treatment Practices for Urothelial Carcinomas

Diagnosis and prognosis. As previously mentioned, most bladder cancer
patients are diagnosed due to incidence of hematuria that is followed by
evaluation by cystoscopy (32). Abnormal findings potentially indicating papillary,
solid, muscle-invasive, or carcinoma in situ lesions require histological
confirmation obtained from biopsy or transurethral resection of the tumor area
(33). Commonly, urine cytology is measured in conjunction with cystoscopy to
detect missed cancer: shed abnormal cells can indicate the presence of
cancerous lesions (34). Expectedly, bladder cancer prognosis and disease
management depend on classification of either NMIBC or MIBC lesions, staging,
and grading (7, 35, 36). In low grade NMIBC tumors (Ta, T1), recurrence is
usually common, but with low risk of progression; in high grade NMIBC tumors
(majority T1, CIS), often regarded as precursors to development of invasive
cancer, progression rates range from 40-83% if tumors are left untreated (37).
MIBC tumors (T2, T3, T4), even after aggressive chemotherapy and radical
cystectomy have recurrence rates of 20-30% for T2, 40% for T3, and >50% for
T4 staged lesions (38). These patients also have shown a 5-year overall survival
rate of less than 30% (39); additionally of note, initially diagnosed NMIBCs that
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have progressed to MIBC show worse overall prognosis and cancer-specific
survival as compared to primary diagnosed MIBC (40).

Management and treatment. All newly diagnosed bladder tumors undergo
endoscopic resection, typically as part of diagnostic cystoscopy. This procedure,
transurethral resection of bladder tumor (TURBT), is performed to remove all
visible tumor and provide an appropriate sample for accurate pathologic staging
(33). Multiple guidelines are available for recommended management of bladder
cancer, but in general, NMIBCs are typically managed by TURBT and risk-based
intravesical therapy with Bacillus Calmette-Guerin (BCG), while MIBCs are more
insistently treated with radical surgery with or without pre-surgical systemic
therapy of chemotherapy, radiation, or immunotherapy (7, 35, 41, 42).
TURBT. TURBT is performed by passing an electrified-wire loop resectoscope
through the urethra during local or general anesthesia, resecting the tumor in a
piecemeal fashion until all visible tumor is removed (43). Patients with low-risk
disease, identified by solitary, Ta tumors that are <3 cm in size, are often treated
by an initial TURBT followed by routine surveillance by cystoscopy for up to 5
years, with future recurrences treated with additional TURBT (42). Intermediateand high-risk patients, identified by larger, multifocal or recurrent Ta tumors, T1
tumors, or CIS, follow initial TURBT with lifelong surveillance, potential repeat
TURBT, and adjuvant immunotherapy with intravesical BCG (42). Unfortunately,
understaging disease is a serious risk for patients, caused by incomplete
resection due to tumor multiplicity, size or location, and results in inadequate
treatment and higher probability of disease relapse and progression (44, 45).
Thus, it is important and recommended for high-grade disease to be resected
12

again when incomplete resections have occurred, or when the tumor invades
past the urothelium, to improve staging accuracy and patient survival (46, 47).
Traditional TURBT as treatment for more advanced disease is not highly
practiced due to chance of bladder perforation and the inevitable decision for
removal of the bladder (48).
Intravesical therapy. Bladder cancer patients with intermediate- and high-risk
NMIBC disease typically undergo adjuvant intravesical therapy with BCG. BCG,
or Bacillus Calmette-Guerin, is an attenuated mycobacterium originally
developed as a vaccine for tuberculosis (49). It was found to provide antitumor
activity in urothelial carcinoma by intravesical instillation into the bladder by
decreasing recurrence and inhibiting tumor progression (50). BCG acts as an
immunotherapy, in that it stimulates a local inflammatory response characterized
by an influx of granulocytes, monocytes and dendritic cells, and induced
expression of inflammatory cytokines such as TNF-, GM-CSF, IFN, IL-2 among
others (51). This inflammatory response is believed to activate a cytotoxic cellmediated killing of tumor cells, producing the efficacy of BCG in preventing
recurrence and progression (52). In North America particularly, patients treated
with BCG exhibited a 68% complete response rate compared to 47% of patients
receiving chemotherapy (53). Adjuvant therapy with BCG includes maintenance
therapy (follow up instillations after initial treatment course) for 1-3 years
depending on disease risk to further reduce incidence of tumor progression.
Patients who have tumor recurrence/relapse, disease progression, or have
intolerable adverse effects while on maintenance therapy or after treatment
course of BCG are deemed “BCG unresponsive” or “BCG failures” (54). For
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these patients, there are few alternative therapeutic options to radical
cystectomy, although bladder preservation strategies including chemotherapy,
investigational immunotherapeutic agents, and clinical trials may be considered
(55).
Cystectomy. For patients with high grade NMIBC, BCG unresponsive NMIBC,
and MIBC, cystectomy (surgical removal of the bladder), or radical cystectomy
with lymph node dissection is the gold standard of treatment. Radical cystectomy
in men includes prostatectomy, and in women includes hysterectomy, and partial
excision of the vagina and urethra (5). Following radical cystectomy, urine is
diverted from its normal pathway by a segment of intestine into either a newly
constructed neobladder (intestine segment with anastomosed ureters) which can
still provide continence, or into a non-continent ileal conduit diversion brought to
the skin as a stoma for use with an urostomy bag (56). Survival outcomes postradical cystectomy depend on final pathological staging of the removed bladder
and tumor. The 10-year recurrence-free survival is 76% for patients staged T1T3a, 61% for T3b, and 45% for T4 when lymph nodes are not involved in cancer
progression/stage, but when lymph nodes are involved survival drops to 34%
regardless of stage (8). Radical cystectomy can seriously affect patient quality of
life, and so much effort is being put towards perioperative care and Enhanced
Recovery after Surgery (ERAS) protocols.
Systemic therapy. Neoadjuvant and adjuvant chemotherapy are used mostly in
MIBC patients both prior to and directly following radical cystectomy to varying
results. Typically, platinum based chemotherapy is efficacious used in a
gemcitabine-cisplatin combination, producing a decrease in risk of death after
surgery and a reduction in diseases recurrence (57, 58). In the neoadjuvant
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setting, arguments for cisplatin-based chemotherapy use include its potential to
downstage bulky and invasive tumors which can improve surgical outcomes, but
its use can also delay other therapies and allow disease progression if patients
do not respond (11). Patients who are diagnosed with metastatic disease initially
or following cystectomy are treated with standard of care cisplatin-based
chemotherapy combinations such as methotrexate, vinblastine, doxorubicin,
cisplatin (M-VAC), cisplatin, methotrexate, vinblastine (CMV), or gemcitabinecisplatin plus paclitaxel (59). However, most patients with metastatic disease,
while initially responsive to systemic chemotherapy, will ultimately progress with
a median survival of 14 months and an overall 5-year survival rate of 5-20% (60).
Typically given in combination with chemotherapy rather than single
modality for optimal survival improvement (61), radiation therapy or
chemoradiation can be used in bladder preservation protocols when radical
surgery has substantial quality of life consequences. These treatments are
subsequent to TURBT (together deemed trimodal therapy) and can result in 5year cancer-specific survival rates between 50-82%, although roughly one-fourth
of patients will eventually need to undergo radical cystectomy due to lack of
response (62).
Systemic immunotherapy has more recently come into treatment practices
in MIBC with the recent US Food and Drug Administration approval of
atezolizumab (anti-PD-L1 mAb) and nivolumab (anti-PD-1 mAb) for treatment of
advanced and metastatic urothelial carcinoma (63). Initial results as a secondline treatment have been promising enough that clinical trials are ongoing for
first-line care, and patients in earlier stages of urothelial cancer.
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Investigational therapy. Due to frequency of recurrence of NMIBC despite BCG
induction and maintenance treatments, and the life-changing decision for
cystectomy, new treatments are being investigated for use in BCG unresponsive
patients. Oncolytic viruses and adenoviral-mediated interferon- (Ad-IFN2b) are
being explored as intravesical therapies to not only target cancer cells, but also
to stimulate the host immune system to fight tumors cells as well (64, 65). Early
clinical trials of Ad-IFN2b gene therapy has shown safety and efficacy with 43%
of patients exhibiting complete response at an average of 31 months, and 35% of
patients free of high-grade recurrence at 1 year (66, 67). Many bladder tumors
harbor molecular alterations that are potentially druggable, such as FGFR3 or
alterations in the PI3K-AKT and MAPK pathways, and many clinical trials are
enrolling and investigating the therapeutic potential of targeted therapies in
bladder carcinoma (NCT02465060, NCT03410693, NCT03047213). As
mentioned above, systemic immunotherapy with checkpoint inhibition in
treatment of MIBC and NMIBC is a current area of investigation. The mechanism
and functional importance of these will be further discussed in proceeding
sections.
Together, once diagnosed, it is necessary for proper stratification of
bladder cancer patients in order to receive the most effective therapy. However,
the most effective treatment scheme may come at high cost both literally, due to
high disease recurrence and progression rates, and figuratively, as patients can
face serious challenges to their quality of life depending on their disease and the
appropriate therapeutic action. For MIBC patients, standard of care radical
cystectomy in combination with chemotherapy or immunotherapy provides the
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best survival outcomes. For NMIBC patients, tumor resection followed by
intravesical BCG are standard practice generating ~70% complete response
rates; but for those that are deemed BCG unresponsive, no effective second-line
therapy exists as an alternative to cystectomy (68-70). These patients make up a
target population for investigational therapies that can improve prognosis, aid in
the preservation of bladders and nullify life-altering surgical intervention.

1.1.3: Potential of Biomarkers for Early Detection, Diagnosis, and Response

Early detection and diagnosis. Early screening of high-risk patients as a
potential option for early detection for bladder cancer is not a viable option owing
to the lack of genetic markers and heredity of the disease. However, due to the
invasiveness and cost of cystoscopy and biopsy as diagnostic tools, there is a
strong desire among the field to identify novel, noninvasive diagnostic methods.
Cytology is often performed in the diagnosis of urothelial carcinoma, to serve as
a backup mechanism for detecting malignant cells originating from the bladder
that a cystoscopy may overlook (71); within the premise of cytology lies the
potential for urine-based tumor markers for early cancer detection and diagnosis.
Several proteomic based tests have been approved by the FDA for diagnosis
and surveillance, but many of these tests are below 80% sensitivity and range
from 60-90% in specificity (72-74). Liquid biopsy detection of urinary markers by
cell free DNA (cfDNA) have been used prognostically in identifying bladder
cancer recurrence, progression and metastasis (75, 76). Urinary detection of
DNA methylation status has been used for risk stratification and to differentiate
bladder cancer patients from controls at sensitivities > 90% (77, 78). MicroRNAs
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(miRNAs) and expression of other genes in voided urine are also being studied
for diagnostic testing to mixed successes, with sensitivities ranging from 71-94%
and specificity from 51-100% (72, 79). However, despite the emerging evidence
of the utility of urine molecular diagnostic markers, currently there are no urinary
based tumor markers that are definitively able to detect bladder tumors based on
sensitivity and specificity (80, 81).

Markers of response. Many therapies for bladder cancer, like BCG, have been
used for decades, and yet there is still no tool to aid in stratification of patients as
likely responders and non-responders to therapy. Kamat and colleagues describe
a urinary cytokine based assay that could predict the likelihood of tumor
recurrence with 85.5% accuracy based on changes in a panel of nine induced
cytokines after BCG therapy (82). Research on urinary exosomes as a marker for
therapeutic response has been investigated in prostate cancer, but remain to
show convincing evidence of correlation with response (83). To date, risk
stratification models based on clinicopathological features from biopsied
specimens remain the most widely used tools available to predict therapeutic
response in bladder cancer (84). Future utilization of biomarkers in the detection
of cancer (predictive) and response to therapy (prognostic) will require validation
to minimize false-negative results, but their potential shows great promise in
directing the field toward improved patient care and treatment strategies.

1.1.4: Summary
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Bladder cancer is a malignancy most often associated with older men, with a
fairly stable incidence outlook as tobacco usage and exposure has been
ingrained in daily life worldwide. Bladder cancer can be subtyped by several
different phenotypic and genotypic aspects, but clinical stratification is based on
tumor invasion status into the muscular wall of the bladder (NMIBC vs. MIBC)
and pathological grading. While the standard of treatments for NMIBC are costly,
though effective for the majority of patients, there is room for improvement
particularly for those who have failed BCG. Standard treatments for patients with
MIBC greatly affect quality of life and survival outcomes, so the continued
investigation into immunotherapy and bladder preservation strategies is crucial.
Improving the treatment and survival of patients with bladder cancer will require
further development of early detection tools and more effective local and targeted
therapies moving forward. Exploring the role of the immune response to foreign
signals and tumors, and the mechanisms tumors use to evade the host defense
system will be reviewed in the next section.
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1.2: The Immune Response and Tumor Immunity

The human immune system as we know it today is a product of evolution,
originating from an archaic defense mechanism which used protein receptors to
recognize common features of dangerous pathogens (85). The first line of
defense for animals, known as the “innate” immune system, involves fastresponding molecules and cells that rush to the site of an infection. The innate
response is often sufficient to contain and eliminate sources of danger to the
host, and is therefore a very important first step in host protection. Higher
organisms later developed a secondary immune response, a predominantly
cellular mechanism intricately designed to target pathogens based on specificity,
and be able to mount a quicker defense response in the incidence of recurrent
infection, otherwise known as “adaptive” immune memory. Although
evolutionarily created to identify and fend off invasion and infection by
microorganisms, the same principles of recognizing a “foreign” molecule that
initiates a cellular and molecular immune response can be applied to cancer.
Cancer is known for its loss of normal cell regulatory function and gain of
innumerable genetic alterations (86). These alterations and dis-regulations have
been known to result in the expression of antigens, leading to presentation of
“foreign” peptides recognized by MHC molecules on surveilling immune cells
(87). In a normal immune response, this peptide presentation and recognition by
an immune cell would result in elimination of the tumor cell. Unfortunately,
despite the ability of our inherent defense system to recognize and kill cancer
cells, the durability and persistence of tumors presumably meant that something
was hindering our immune cells from destroying it. Definitive proof of these
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immune inhibitory mechanisms was found in mice, when Dunn and colleagues
discovered that cancer cells had the unique ability to delete T cell targets and
thus avoid being detected and attacked (88). Tumors can also suppress an
immune response by activating negative regulatory pathways that exploit
immune homeostasis and inhibit immune cell effector functions (89, 90). Deemed
tumor-immune “evasion” or “escape”, these mechanisms allow tumors to survive
in an environment that would normally prove hostile.
The following section provides a background on the normal mechanisms
of immune response when foreign antigens are discovered, including responses
of the innate and adaptive arms of the immune system, and will also provide a
discussion on the specialties of tumor-immunology and the mechanisms of
tumor-immunosuppression.

1.2.1: Overview of Innate vs. Adaptive Immune Response to Foreign or Tumor
Signals

Innate response. As touched on above, the innate immune system biologically
evolved as the first line of defense against pathogens. Innate immunity usually
encompasses the myeloid derived lineage of phagocytic and inflammatory white
blood cells (neutrophils, monocytes, macrophages), complement, cytokines, and
acute phase proteins, all of which are designed to provide immediate response to
signals of infection or damage (91). These responses are hard-wired from
germline encoded genes to recognize molecular patterns common to microbial,
toxic, or allergenic structures that are not present in the host (92). Membraneassociated proteins called pattern-recognition receptors (PRRs) recognize
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essential microbial components known as pathogen associated molecular
patterns (PAMPs) and host tissue distress signals known as damage-associated
molecular patterns (DAMPs) (93). PRRs are constitutively expressed on large
numbers of cells, and once activated, initiate specific signaling pathways to
eliminate the foreign invader (94). PRRs can be differentiated by their expression
patterns and ultimate function, generally either classified as cytoplasmic
receptors (NLRs, RLRs) or membrane-bound receptors (TLRs). Toll-like
receptors (TLRs) are one class of transmembrane PRRs that have been
evolutionarily conserved across species, existing as either extracellular or
intracellular signaling proteins that recognize microbial lipids and nucleic acids
(Table 1) (94). Most prominently expressed on antigen-presenting cells (APCs)
including macrophages and dendritic cells (DCs), stimulation of receptors with
a TLR ligand (microbial component) initiates a signaling cascade driven by
either MyD88 or TRIF adaptor molecules, resulting in the production of proinflammatory cytokines and type I interferons (IFN), respectively (95, 96). IFN
and cytokines serve to further recruit and activate more immune cells and lead
to pathogen destruction, to be discussed more in depth below. TLRs were
among the first targets validated for cancer immunotherapy based on the
clinical efficacy of BCG therapy, an agonist of TLR2 and TLR4, in patients with
early-stage bladder cancer (97). Exploitation of TLR signaling continues to be
explored and utilized in many cancer therapies today.
The other major class of PRRs, cytoplasmic receptors including RIG-I
like receptors (RLRs), cytosolic DNA sensors, and nucleotide-binding
oligomerization domain [NOD]- leucine-rich repeat containing receptors
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(NLRs), are associated with recognition of bacterial and viral components in
Table 1: Recognition by Toll-Like Receptors (TLRs)
PAMP Recognition
DAMP Recognition
Location

TLR

1
2
3
4
5
6
7

Lipoproteins, peptidoglycans,
lipopolysaccharides
Lipoproteins, peptidoglycans,
BCG
dsRNA, viral RNA, tRNA,
siRNA, poly(I:C)
lipopolysaccharides (LPS),
BCG
Flagellin
Lipopeptides (mycoplasma)
ssRNA, imidazoquinolines,
guanosine analogs

8 ssRNA, imidazoquinolines
viral DNA, CpG DNA, CpG
9 ODNs

Heat shock proteins
(HSPs), proteoglycans
mRNA
HSP60, 70; Fibrinogen

ssRNA
ssRNA
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Signal Adaptor

cell surface

TIRAP, MyD88

cell surface
intracellular,
endosomes

TIRAP, MyD88

cell surface
cell surface
cell surface
intracellular,
endosomes
intracellular,
endosomes
intracellular,
endosomes

TRIF
TRAM, TRIF, TIRAP,
MyD88
MyD88
TIRAP, MyD88
MyD88
MyD88
MyD88

the cytosol (98). NLR family members can sense intracellular bacterial
peptidoglycans, cellular stress products, microbial products, and noninfectious
crystal particles (99). The most common family members of NLRs, NOD1 and
NOD2 and NLRPs, form oligomers once activated to further initiate production
of other inflammatory cytokines, active NF-kB inflammatory signaling, and
induce the inflammasome complex which leads to the cleaving and secretion of
IL-1 family members (100, 101). RLRs are RNA helicases that recognize
cytosolic dsRNA and are particularly important in viral infections. Unlike TLRs,
RLRs are expressed by most cell types. The most described RLR helicases
are retinoic-acid-inducible protein I (RIG-I), melanoma differentiation
associated gene 4 (MDA5), and LGP2, which when stimulated initiate a
cascade to increase production of inflammatory cytokines and type I IFN, like
NLRs and TLRs (98). Similarly, cytosolic DNA sensors like STING and cGAS
detect viral and cytoplasmic DNA and initiate a type I IFN inflammatory
response.
Surveilling phagocytes based in common entry tissues and PRRexpressing epithelial cells are among the first responders to foreign pathogens.
Upon PRR recognition, they initiate an NF-kB-mediated signaling cascade of
cytokines to stimulate inflammation within the infected tissue, causing more
DCs, macrophages, and other innate cells to produce cytokines and
chemokines to attract circulating leukocytes and begin the first stages of the
cellular arm of the innate response (102). These cytokines are considered proinflammatory, and are important in staging the innate defense, but once
mounted they must also be regulated to eventually subside to prevent
extensive tissue damage (103). Common inflammation-induced cytokines and
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chemokines include IL-1, IL-6, IL-12, TNF, IFN, IL-4, IL-10, IL-18, CXCL8,
CCL4, RANTES, TGF and later GM-CSF and M-CSF, with functions ranging
from monocyte differentiation, increasing vascular permeability, further immune
cell recruitment, lymphocyte activation, and the suppression of response (104,
105). The early response cytokines TNF and IL-1 increase expression of celladhesion molecules such as selectins and integrins to attract monocytes and
neutrophils to the site of infection (106). Chemokines CXCL8, CCL4, and
RANTES are chemotactic cytokines, serving to recruit neutrophils, basophils,
monocytes, T cells and other immune cells by their sensing of these small
molecules in a gradient fashion with highest concentrations at the source of
infection (107). IL-4, IL-10, and TGF generally serve as anti-inflammatory
cytokines by negatively regulating the innate response. IL-10 and TGF
suppress DC differentiation, inhibiting their ability to activate T cells, and can
also directly inhibit T cell functions; they negatively regulate pro-inflammatory
cytokine production and cytotoxic cell function, and induce differentiation of
regulatory T cells, but have a role in tissue repair (105, 108). IL-4 is initially
produced by mast cells and is important in protecting the host during parasitic
infection (109). IL-4 has mixed roles in the inflammatory response: its
important in the differentiation of monocytes into DCs and B cell activation, but
following the cellular activation of the innate response, IL-4 also induces T cell
differentiation into Th2 type cells (110, 111). IL-12 and IL-6 have roles in
activating lymphocytes and inducing Th1 type immune differentiation (105,
112). TNF- and IL-1 in combination with IL-6 are also important for initiating
the acute phase response and opsonization-mediated pathogen killing (113).
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TLRs, RLRs, and STING sensors are the major pattern recognition
receptors that are stimulated to signal type-I interferon (IFN-I) production. Type
I interferons (IFN- and IFN-), induced from sensing for foreign (viral) nucleic
acids by TLR3,4,7,9, RIG-I and MDA-5, are produced by almost all cell types;
however the major production of IFNs-I comes from plasmacytoid DCs (pDCs)
(114). Both IFN- and IFN- induce resistance to viral replication in all cells,
hence the name “interferon”, through the JAK/STAT signaling cascade which
culminate in the transcriptional regulation of many interferon-stimulated genes
(ISGs) (115). Signaling through PI3K/AKT, NF-kB, and MAPK are also
triggered by activation of the IFN receptor, resulting in induction in cell division,
proliferation, differentiation, and survival (116, 117). IFNs-I exert effects on the
immune response directly by stimulating innate cells to activate other cells, and
indirectly through the induction in chemokines, such as CXCL9, CXCL10 and
CXCL11 for immune cell recruitment, and the induction of cytokines important
in regulating innate and adaptive cells (118-120). IFNs-I support the migration,
maturation, and differentiation of monocytes into DCs thereby upregulating
antigen presentation, as well as macrophage cytotoxicity and phagocytosis
(121, 122). They also increase MHC class I molecule expression to enhance
antigen recognition by antigen presenting cells (APCs; DCs and macrophages)
and encourage DC migration, together with priming and activation of the
adaptive immune response (123-126), to be discussed further in the next
section.
As touched on above, IL-6 is a very pleotropic cytokine induced by PRR
recognition of PAMPs and DAMPs, NF-kB signaling, and IFN-I signaling from
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immune cells, but also from fibroblasts, endothelial cells, and other cells (127).
Like other cytokines (IL-4), IL-6 is known for both pro-inflammatory and antiinflammatory actions. Differences in its roles may be linked to the different
ways IL-6 signals at the plasma membrane: 1) classical signaling involves
membrane IL-6R binding with receptor protein gp130, but not every cell type
has membrane-bound IL-6R, and so 2) soluble IL-6/IL-6R (sIL-6R) is utilized
and known as IL-6 trans-signaling (128). Binding of IL-6 to IL6-R and gp130
initiates JAK/STAT or MAPK signaling pathways, the former simultaneously
inducing a negative feedback loop to suppress IL-6 by SOCS genes (129). IL-6
contributes to immune defense in a pro-inflammatory role by inducing the acute
phase response, hematopoiesis (granulopoiesis), B cell differentiation, and
interferon-like activity (130, 131). It also promotes differentiation of CD4 T cells
in to Th17 T cells and suppresses CD4 T reg formation, and induces CD8
cytotoxic T cell differentiation (132-134) (Figure 3). If left unchecked, these
pro-inflammatory responses contribute to development of chronic inflammation
and autoimmune diseases (135, 136). Anti-inflammatory effects of IL-6 include
a role in wound healing and liver regeneration (137), and negative regulation of
pro-inflammatory TNF, GM-CSF, IFN, and MIP-2 cytokine production in
acute lung inflammation (138). In relation to cancer and disease pathology, IL6 is a known instigator of autoimmune disease such as rheumatoid arthritis and
colitis caused by chronic inflammation (139), and has been linked to antitumorigenic and pro-tumorigenic actions with poor clinical outcomes in cancer
patients (140). IL-6 has controversial roles in immune activation, chronic
inflammation and cancer, but it remains a strategic bridge connecting the
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Figure 3: IL-6 in inflammation, immune response, and pathogenesis. IL-6 is
a pleiotropic cytokine. It induces acute phase response proteins such as CRP,
serum amyloid A, fibrinogen and hepcidin from hepatocytes. IL-6 also plays an
important role in adaptive immunity by stimulating B cell and T cell differentiation
and function. IL-6 can also promote proliferation of many immune and nonimmune cells. RANKL, receptor activator of nuclear factor kB (NF-kB); VEGF,
vascular endothelial growth factor. This figure was taken with permission from
Tanaka T, Narazaki M, Kishimoto T. 2015. IL-6 in inflammation, immunity, and
disease. Cold Spring Harbor Perspectives in Biology (136). License number
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innate and adaptive immune responses.
Natural Killer cells (NK cells) serve as a special component of the innate
immune system. NK cells have similarities to both innate and adaptive cells: they
develop from the same progenitor cells as B and T cells, and have the ability to
kills cells by direct contact after binding cell-surface receptors, however, NK cells
are fast-responding and have invariant, germline-encoded receptors that
recognize molecules on infected cell surfaces, and as such are considered innate
cells (141). NK cells are activated in response to the triggering of their activation
receptors by cognate ligands (142), IFNs-I, and cytokines produced from
macrophages and DCs. Once activated, they then identify infected cells based
on aberrations or loss of MHC class I expression, and directly kill cells by
cytotoxic granule release (perforin) or production of IFN (143-145). Normal class
I MHC expression is an inhibitory signal to NK cells, as this is the sign of self-host
cells (146, 147). Loss of this inhibitory signal (normal class I MHC) was proved to
be insufficient for NK cell killing, and that an additional activating signal was
necessary (148); NKG2D and FcRIIIa (CD16) activating receptors provide the
necessary secondary “kill” signal (149, 150). Further, NK cells can be “primed” by
DCs to be more effective killers (151), and can also exhibit a form of
immunological memory, similar to adaptive cells (152-154). Though able to
provide immune defense by fast response and pathogen receptor recognition,
NK cells have many functional features that make them an intermediate to the
precisely targeted adaptive arm of the immune system.
Innate responses are able to prevent infection from establishing and
spreading by discriminating between foreign pathogens (PRRs) and self, but are
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mostly non-specific. Most of these PAMP signaling pathways by PRRs overlap
with sensing of tissue damage (DAMPs), including tumor-derived antigens (155).
Thus, the innate immune system has a role in recognizing and responding to
cancerous cells. Tumor neoantigens, RNA, and DNA can be sensed by TLRs,
RIG-I (RLR), and STING, triggering the macrophage and DC production of
cytokines, interferons, chemokines, and antigen presentation with T cell priming
(156, 157). The result is cancer cell death by eliciting apoptosis pathways,
interferon signaling, or primed cytotoxic cells (158-160). Increased ligand
expression provided by cellular stress or DNA damage of tumors cells help
activate NK cells via their activating receptors (161) and cause direct tumor cell
death by cytotoxic granules (perforin, granzymes), Fas-ligand or TRAIL,
secreting IFN, and through antibody-dependent cellular cytotoxicity (162).
Not only is the innate immune response of key importance in the initial
stages of host defense, but it is also essential to the adaptive response, as the
cells stimulated by microorganisms during infection, or tissue damage-associated
tumor antigens, go on to activate antigen-specific defense directly and through
cytokines and chemokine migration. PRR signaling that leads to macrophage
and DC maturation, antigen presentation, and type I interferon production, in
combination with NK cell pathogen recognition and activation, provide
mechanisms of containment, whistle-blowing, and killing. These necessary first
steps provide sufficient time for the induced T and B cell adaptive responses with
high tumor cell specificity and cytotoxicity, explained further in the next section.
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Adaptive response. As previously mentioned, the immune response consists of
two arms: the innate component, an immediate though non-specific response
consisting of myeloid cell pathogen sensing and cytokine and chemokine release
for cellular recruitment and activation; and the adaptive component, a delayed
but intricately more specific response largely reliant on the lymphocytic lineage of
cells. Many of the responses of innate immunity are necessary for the adaptive
immune system to get started. In brief, dendritic cells that are stimulated by PRR
recognition increase their surface expression of MHC class II receptors and costimulatory molecules which will allow them to activate naïve T cells once they
migrate to peripheral lymphoid tissues and present antigen (163, 164). Once the
lymphocytes are activated, the DCs die, and the T cells begin to proliferate and
mature into cytotoxic CD8 effector T cells (165). The cytokines produced by the
innate cells also encourage differentiation of naïve CD4 cells into Th1, Th2,
Th17, TFH, or Treg effectors (166, 167), which then after DC activation, are able to
‘help’ stimulate the antigen receptors of B cells to an effector state, or
differentiate into plasma cells, and produce secreted antibodies against
pathogens (168-170). Once activated, effector T cells reenter circulation and
migrate back to the site of infection, following chemokine gradients and adhesion
molecules (171). Serving as the cell-mediated responders of adaptive immunity,
CD8 T cells can directly kill aberrant cells while CD4 T cells help to activate
macrophages, neutrophils, and secrete protective and activating cytokines to aid
in defense (172-174). Activated plasma B cells secrete antibodies specific to the
foreign antigen to eliminate pathogens by humoral neutralization, opsonization,
or complement activation (175). Thus, the adaptive response relies heavily on
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innate immunity to be initiated and guided in order to achieve precise immune
protection and disease resolution.
Originally, T and B lymphocytes develop from a common progenitor stem
cell in the bone marrow (HSC), but T cell progenitors must migrate to the thymus
for further stages of development into T cells. In the thymus, T cell progenitors
acquire antigen-specific receptors, known as TCRs (T cell receptor), by random
somatic rearrangement of DNA segments that specifically code for antigen
binding regions of the receptor through a process called VDJ (variable-diversityjoining) recombination. In total, VDJ recombination can produce up to 108
different TCRs to match the wide variety of potential antigens (176), which are
then further selected by their TCR reactivity to self-antigens (negative selection)
and expression of CD4 or CD8 (positive selection based on class I (CD8) or
class II (CD4) MHC molecules). Once T cells pass through selection and
complete development, they home to secondary lymphoid organs such as the
spleen or lymph nodes, and proceed to continuously circulate through these
organs, lymph, and blood, awaiting the potential of antigen recognition and
shedding their naïve status (177). Stimulated DCs, with antigen in tow, traffic
from the origin of pathogen recognition to the inflamed or “reactive” lymph node
and encounter scanning T cells, while concomitantly expressing CD80 and CD86
co-stimulatory molecules (178-180). When an antigen-naïve T cell recognizes its
cognate antigen presented on the MHC molecule of an APC, the T cell
undergoes several changes: If the peptide is presented on an MHC class I
molecule, which is broadly expressed on all cells, and activating cytokines such
as IL-12 and IFN-I are present, naïve CD8 T cells will differentiate in to cytotoxic
CD8 cells and undergo clonal expansion. If the antigen peptide is presented on
32

an MHC class II molecule, naïve CD4 T cells will differentiate into various CD4
helper T cell subsets, dependent on the cytokines present in the environment, to
be elaborated on in the next paragraph. Additionally, T cell activation
upregulates the expression of CD69 surface molecules to ensure the T cell stays
in the supportive environment of the lymph node, with antigen, co-stimulation,
and cytokines present, promoting proliferation of high (and moderate) antigenaffinity T cells specific to that cognate antigen, called clonal expansion (181,
182). During clonal expansion, the majority of expanded T cells down regulate
CD62L and CCR7, allowing them to exit the lymph node and migrate to the sites
of antigen source by way of chemokine gradients, integrins, and selectins, and
perform their effector functions (183). For CD8 T cells, those effector functions
include TNF and IFN cytokine production, and most especially, cytotoxicmediated cell death of the target cell recognized by its specific antigen
peptide/MHC class I complex (184). This cytotoxic function is accomplished by
cell-cell contact and delivery of perforin and granzyme toxic granules into the
cytosol of the infected cell, lysing and killing the target cell (185, 186).
When DCs present antigen peptide on MHC class II receptors, naïve CD4
T cells are activated to differentiate into multiple subtypes of effector and
regulatory CD4 cells. After stimulation with antigen, CD4 cells begin to produce
IL-2 to further promote their proliferation, and proceed towards differentiation into
Th1, Th2, Th17, Treg, or TFH depending on the cytokines present at the activation
site (187). IL-12 and IFN produced by macrophages and NK cells induces the
differentiation of Th1 cells (188). Th1 cells are effector cells that support cellmediated immune response; they express transcription factor T-bet, and produce
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IL-2 and IFN to support macrophage and T cell proliferation and cytotoxicity
(189), and protect the host from bacteria and viruses. IL-4 from basophils, mast
cells, and eosinophils encourage differentiation into Th2 cells (190). Th2 cells are
characterized by expression of transcription factor GATA3, are thought to support
more humoral and allergic responses and defense against parasites, and
produce suppressive cytokines IL-4, IL-5, and IL-13 (191). Th17 cells arise when
IL-6 and TGF are present and are more pro-inflammatory cells, expressing the
transcription factor RORT and producing IL-6 and IL-17 cytokines (192). They
help to recruit neutrophils to the site of infection. TFH cells, or follicular helper
cells, express the transcription factor Bcl6, and exist in the lymphoid follicles to
help stimulate B cells to produce high-affinity antibodies (193). Unlike the other
effector cells, cytokines involved in TFH differentiation are not completely known,
but IL-6 is known to be important (194). TFH cells can produce cytokines that are
similar to those of Th1 and Th2 cells, signaling to B cells which antibody isotype
to secrete (195). Effector CD4 cell responses act in defense by producing
cytokines and chemokines that activate and recruit other immune cell subsets to
their effector states. Because of this broad reaction, CD4 cells need to be more
tightly regulated than the specific response of CD8 cells, and so only certain
types of antigen presenting cells have MHC class II molecules. Treg, or regulatory
T cells, also serve in this purpose. Treg cells suppress the immune response, and
are key in preventing autoimmunity, by secreting IL-10 and TGF (196). There
are two main groups of regulatory T cells: natural and inducible. Natural Tregs are
committed to a regulatory fate while still in the thymus, and have high levels of
surface CTLA-4 expression; inducible Tregs differentiate from naïve CD4 T cells in
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the periphery under the influence of the environment (105). Induced Tregs arise
when TGF alone is present in the lymph tissue, and like natural Tregs, induced
Tregs express the FOXP3 transcription factor which prevents the transcription and
production of IL-2 (197). CD4 and CD8 T cell differentiation are critical in host
defense and entirely dependent on the type of cytokine signals produced from
pathogen-activated innate cells, underlining the cohesiveness of the immune
response.
As mentioned before, B lymphocytes differentiate from the same common
progenitor as T lymphocytes, however B cells remain in the bone marrow. Like T
cells, B cells also generate surface antigen-specific receptors, called B cell
receptors (BCR), by way of somatic VDJ recombination (198). Unlike TCRs
though, BCRs are expressed as an immunoglobulin molecule (Ig) with heavy and
light chains that make up the antigen binding domain (199). The recognition of
antigen by BCR not only can activate the naïve B cell directly, in conjunction with
TLR stimulus (200), but it can also be internalized, processed, and presented
back on MHC class II molecules for further antigen-specific CD4 T cell
stimulation (201). The stimulated CD4 T cell then binds to the B cell by CD40
ligand interaction, and produces activating cytokines for B cell proliferation and
differentiation into antibody-producing plasma cells (202-204). IL-4, IL-5, TGF,
or IFN are selectively secreted depending on the type of pathogen detected to
induce specific antibody class production (205). Once secreted, antibodies
function to kill the foreign pathogen by neutralization, opsonization, or
complement activation (206). Neutralization involves antibody binding to bacterial
toxins and viruses to prevent their interaction with normal host cells (207, 208).
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Antibodies activate the complement immune response by binding the first
complement proteins to the Fc region of the antibody, ultimately resulting in
opsonization and phagocytosis, killing of the pathogen (209). The Fc region of
antibodies can also activate other immune cells like NK cells to induce pathogen
elimination (210, 211).
Cellular and molecular components of the innate and adaptive immune
responses work together to resolve pathogen infections, tissue damage, and
foreign bodies. For most acute diseases, once the danger is resolved, the
inflammatory stimulus is removed and effector cells undergo apoptosis and
phagocytosis. Some effector cells remain and differentiate into memory cells (B
and T), who have the benefit of faster response times if the original pathogen or
damage recurs (212, 213). Together, the immune response is the most powerful
line of defense and management of infections, tumors, and disease. The inherent
processes of both the innate and adaptive arms provide major targets for
treatment strategies in effort to optimize the events that naturally occur. However,
despite its effectiveness in protection and pathogen elimination, microorganisms
and malignancies like cancer have developed ways to subvert the immune
response, which will be addressed further in the following section.

1.2.2: Mechanisms of Immunosuppression in Tumor Immunity

As touched on previously, the genetic alterations and changes in cell
regulatory processes in cancer cells often produce antigens from mutated genes,
overexpressed genes, or cellular distress (DAMPs) (214, 215) that can be
recognized by surveilling immune cells. These tumor antigens, either presented
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on the cell’s MHC class I molecule or released from the cell in death, are sensed
or picked up by APCs (macrophages and DCs) via TLRs, RLRs, or other
sensors, triggering a pro-inflammatory response, and antigen processing and
presentation (216). Once activated by these “danger” signals, APCs upregulate
co-stimulatory ligands and traffic to proximal lymphoid tissue, such as the tumor
draining lymph node, to prime the adaptive T cell and B cell response (217, 218).
CD4 T helper 1 cells (Th1), CD4 T helper 17 (Th17) cells, CD8 T cells, and B
cells in combination with NK cells and the other innate immune cells all play
important roles in tumor inhibition by mechanisms similar to those for foreign
pathogens (219, 220). Despite the host’s ability to stage an immune-mediated
antitumor response however, incidences of tumor eradication, even with
therapeutic assistance, are rare. In order to avoid elimination, tumors have
developed strategies to evade immune detection, hinder immune activation,
block tumor infiltration, and inhibit tumor-killing mechanisms. This section will
provide an overview of the most common mechanisms of immune suppression
co-opted by cancer cells to escape eradication, focusing on the immune cell
types primarily affected.

Loss of antigenicity and inhibition of sufficient immune activation by APCs.
Tumors have developed a wide variety of ways to avoid detection by APCs as
well as activated T cells. These evasive mechanisms result in decreased innate
and adaptive cell activation and tumor-killing ability, leaving the tumor to continue
thriving. Tumor cells have been shown to down regulate the expression of MHC
class I molecules, evading detection by both DCs during initial surveillance, and
antigen-specific T cells during the adaptive response (221, 222). Loss of MHC
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class I molecule expression in tumors is associated with poor disease prognosis
and clinical outcome (221). Tumor secreted factors such as VEGF (223), IL-6,
and M-CSF (224) also cause defects in DC differentiation and maturation,
resulting in less expression of MHC class II molecules and lack of expression of
co-stimulatory molecules CD80 and CD86, making them unable to present
antigen to T cells and activate the T cell response (225, 226). Lack of costimulatory molecules can lead to T cell tolerance, anergy, and T cell death
(227). In addition to the direct effects tumors have on DCs and T cells, tumors
can acquire the ability to delete their own cells that express antigens T cells
recognize, a process called “immune editing” (228). The loss of antigenic
epitopes also occurs from many targeted cancer therapy treatments (229, 230).
This loss of antigenicity can result in the evolution of tumor cell variants that are
not recognizable to immune cells, leading to tumor progression (231, 232). The
NKG2D activation receptor expressed on cytotoxic NK and T cells is a known
responder to damage and stress-induced ligands in cancer. Tumor cells however
can manipulate the expression of these ligands through post-transcriptional and
post-translational regulation by misfolding, adenylating, splicing, or glycosylating
the ligands in order to avoid immune recognition (233). Consequently, down
regulation of antigens and inhibition of immune activation by loss of antigen
presentation and co-stimulation represent two mechanisms utilized by tumors to
evade the immune system.

Immune exclusion. Despite the existence of cancer therapies that are tumorantigen specific, or involve blockade of tumor-suppressive chemical
mechanisms, there remain many tumor types that exhibit little to no antitumor
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response (234). This lack of response could be linked to physical obstacles
prohibiting activated immune cells from infiltrating the tumors (235). The
microenvironment of a tumor (TME) is characterized by not only by cancer cells
and immune cells, but also blood vessels, fibroblastic cells, and extracellular
matrix (ECM) (236). Studies have shown that stromal cells in the TME such as
fibroblasts (cancer-associated fibroblast, CAFs), myeloid-derived suppressor
cells (MDSCs), and tumor associated macrophages (TAMs) and the tumor
vasculature all play a role in preventing immune infiltration. Reactive nitrogen
species produced by MDSCs can trap T cells in the surrounding tumor stroma by
nitration of chemokine CCL2 (237). CAFs can also trap T cells in the tumor
periphery by secreting dense ECM proteins that inhibit T cell migration (238).
High expression of Fas ligand (FasL) on endothelial cells in the tumor
vasculature can induce CD8 cell apoptosis, preventing their infiltration, while
simultaneously not excluding Treg cells because of their inherent high expression
of apoptosis inhibitor c-FLIP (239). This mechanism is known as immune
privilege. Immune cells can also be excluded from poorly vascularized and
hypoxic tumors, caused by rapid tumor growth and expression of HIF-1 (240).
Normalization of tumor vasculature by VEGF inhibition or deleting the signaling
regulator Rgs5 can enhance T cell infiltration (241, 242). Until the problem of
TME barriers can be overcome, the full benefit of immune cell therapies may not
be realized. Thus, prevention of immune infiltration is a key mechanism exploited
by tumors and their co-opted stromal cells in suppressing immune-mediated
elimination.

39

Immunosuppressive ligands. T cell activation is a complex process not only
involving antigen recognition, co-stimulation, proliferation and differentiation, but
it also induces inhibitory pathways that can lead to eventual attenuation of T cell
responses (243). In normal tissue homeostasis, negative-feedback responses
called “immune checkpoints” are crucial to maintain self-tolerance and protect
host tissue from potential damage induced during the immune response to
infection (244). However, tumors and their microenvironment often have
dysregulated expression of immunosuppressive receptors and ligands that
regulate T cell effector functions, providing a mechanism of immune evasion. The
high expression of antigens in cancer can also lead to the deterioration of T cell
effector functions caused by continuous activation stimuli, a state termed
“exhaustion” (245). Therefore, it makes sense that exhausted T cells are also
characterized by expression of multiple inhibitory receptors. Immune inhibitory
receptors such as PD-1, CTLA-4, TIM-3, LAG-3 and their ligands, among others,
are expressed on tumor cells, T cells, and other immune cells in the TME
including DCs, macrophages, fibroblasts, immature MDSCs, and Tregs (244),
making the potential of receptor-ligand binding, and immune escape extremely
likely.
The most well studied immune checkpoints are CTLA-4 and the PD-1/PDL1 pathways. Programmed cell death (PD-1) receptor is induced upon T cell
activation and is intended to limit T cell effector functions by decreasing their
production of inflammatory cytokines and cell survival proteins (246, 247). It’s
ligands, PD-L1 and PD-L2, are most often expressed in peripheral tissues by
tumor cells and myeloid-derived cells in the tumor microenvironment (248). The
PD-1/PD-1/PD-L2 pathway gene expression can be upregulated on tumor cells
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and cells in the TME as a consequence of constitutive oncogenic pathway
signaling (249), and in response to therapy, HIF-1 expression and hypoxia
(250), immune-associated cytokines such as IL-10, TGF and IFN (251, 252),
and tumor-secreted factors such as VEGF and PGE2 (253). PD-1 can also be
induced on NK cells and B cells as well as Tregs, limiting their lytic and effector
activities (254, 255) or promoting their proliferation and immune suppressive
function (256), respectively, exhibiting another mechanism of immune resistance.
Unlike PD-1, cytotoxic T lymphocyte associated protein-4, or CTLA-4,
predominantly regulates T cell activation, but is also important in maintaining
immune tolerance and avoiding autoimmunity, and thus can be found more
broadly in host tissues and secondary lymphoid organs, as well as the tumor
microenvironment (244). CTLA-4, which is expressed upon T cell activation, has
very high homology to CD28 co-stimulatory receptor, but binds to B7 (CD80/86)
receptors on APCs with much higher affinity than CD28; thus, it is believed to
outcompete CD28 for receptor binding, resulting in lack of T cell activation (257,
258). To produce its inhibitory effects, CTLA-4 interferes with the TCR signaling
chain, and by removing the active pool of CD80/CD86 from APC surfaces (247,
259). Despite inhibiting CD8 effector T cells, the major effects of CTLA-4
signaling come from down-modulation of CD4 helper T cell activity (Th2) and
increasing Treg immunosuppressive functions (260, 261).
Other checkpoint receptors have been more recently discovered and
investigated, including TIM-3, LAG-3, BTLA, A2aR, KIRs and others. These
molecules are expressed on T cells, NK cells, and TME-associated endothelial
cells, macrophages, APCs, and Tregs, induced from inflammatory signals and T
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cell activation (244, 262, 263). They have been shown to inhibit NK, CD8, and
CD4 helper T cell activity, cytotoxicity, and promote anergy and T reg proliferation
and function (264-266).
Therefore, immunosuppressive receptors and ligands represent one more
mechanism co-opted by cancer cells to combat the immune response.

Immunosuppressive cells. In addition to the loss of antigenicity and ability to be
recognized, creation of barriers to prevent immune infiltration, and induction of
inhibitory receptors, tumors can co-opt stromal and immune cells in the TME to
aid in suppressing effector cell functions and evade extinction. Often
encompassed in the total tumor infiltrating lymphocytes, Tregs play an important
role in immunosuppression by secreting anti-inflammatory cytokines such as IL10, IL-35, and TGF, competing for activating cytokines like IL-2 with effector
cells (267), and by direct contact with CTLA-4 (268), adenosine (269), and
cytotoxic cytokines to inhibit DCs and effector T cell function (270, 271). Treg
differentiation is induced by antigenic stimulation in the presence of TGF (272),
and naturally formed Tregs can traffic to the tumor site via tumor and macrophage
secreted CCL22 (273). TGF itself can disrupt T cell activation directly as well as
by limiting the mobility and survival of DCs (274), and by promoting polarization
of tumor associated macrophages that sequester tumor antigen (275),
contributing to inhibition of T cell priming. Macrophages and undifferentiated
monocytes in the TME can be influenced by environmental cues to preferentially
differentiate into M2 macrophages (276). M2 macrophages are induced by IL-4
and IL-13, typically produced by Th2 helper cells, and are deemed
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immunosuppressive because they contribute to the production of IL-10 and
arginase, inhibitors of T cell activation (277). Immature myeloid cells known as
MDSCs are recruited to the TME by GM-CSF, IL-6, and CCL2, often produced
from tumor cells (278). Major MDSC-mediated mechanisms of immune
suppression are promoted by TGF- (279) and include nitrosylation of the TCR
and T cell surface proteins to inhibit T cell effector function (280), and expression
of arginase to deplete arginine nutrients from the TME (281). Suppressive
subsets from the myeloid lineage have overlapping abilities to express
immunoregulatory molecules such as arginase, iNOS, and indoleamine 2,3dioxygenase (IDO) to inhibit CD8 cell proliferation or induce apoptosis (282). IDO
and arginase are metabolic enzymes that can catabolize essential amino acids,
tryptophan and arginine, used by T cells for inducing proliferation, cell cycle
growth, and effector functions (283-285). iNOS also catabolizes arginine to form
nitric oxide (NO), a reactive nitrogen species used by MDSCs, utilized for
nitrosylation of the TCR to interfere with TCR binding peptide-MHC complexes
and promote hyposensitivity and tolerance (286), and nitration of chemokines
used in T cell recruitment (237).
Many of the cellular interactions in the TME are complex, showing
redundancy in suppressive action, or cytokine profiles having positive feed-back
loops supporting the differentiation and function of immunosuppressive cells. In
addition to the few mechanisms described here, tumors have many other
immune resistance mechanisms, a product of their constant need for evolution to
maintain survival. It has been shown that tumors can become resistant to
cytotoxic cytokines, shown by the development of tumor-IFN insensitivity from
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the absence or dysfunction of IFN receptor signaling pathway (287). Tumor cells
can also lose the expression of genes necessary for cytotoxic signaling such as
JAK family members and genes of the IFN pathway, promoting resistance to
immune-mediated killing (288, 289).

1.2.3: Summary
The innate and adaptive immune system are evolutionarily advanced in their
ability to cooperate to resolve danger within their host. Humans have developed
intricate pathways to detect foreign pathogens and cancer, following up sensing
with action, by activating the effector cells and molecules of immune protection.
However, tumors have developed ways to counteract and suppress the
defensive activity of our immune system at most turns. The most interesting
aspect of tumor-immune suppression is that most of the cells and molecules
utilized by tumors to promote their own survival are inherently purposed for selftolerance to prevent autoimmunity. Despite this fact, many of the suppressive
mechanisms tumors have acquired such as checkpoint inhibitors and
immunosuppressive cells can be therapeutically targeted to repolarize the TME
into an antitumor phenotype, which will be reviewed in the following section.

1.3: Immune Therapy: Overcoming Tumor-Immunosuppression

As reviewed above, humans are equipped with extensive protective
mechanisms that enable the detection and recognition of foreign pathogens and
damage, or cancer associated markers. This identification process initiates a
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cascade of signaling, recruiting an immediate cellular and chemical response to
instigate inflammation at the source of trouble, killing microorganisms and cells in
a non-specific but timely matter; while behind the curtain, an intricately more
specific immune response ramps up to deliver a precise second wave attack.
Despite the involved, sophisticated, and specific process that is the immune
response, pathogens and cancer in particular have simultaneously evolved ways
to suppress and evade it in order to continue surviving. These include tumorinduced impairment of antigen presentation and negative regulation of APC
function and development; creation of a physical barrier to infiltration T cells by
utilization of fibroblasts and stromal cells in the tumor microenvironment;
promoting upregulation of pro-apoptotic and immunosuppressive cytokines,
ligands, and receptors to inhibit cellular mediators of cytotoxic response; and
drafting and recruiting of immunosuppressive cells from the microenvironment
and circulation to further inhibit effector cells of the immune system (234, 290).
The vast mutational landscape and heterogeneity of tumors between
patients, and even between different areas of the same tumor, make
personalized medicine targeting specific gene mutations challenging. Given the
potent immunosuppressive capacity of tumor cells, infiltrated suppressive
immune cells, the surrounding tumor stroma, and the propensity of immune cells
to respond to cancer antigens in similar ways across patients, targeting the
suppressive pathways tumors co-opt for self-promotion presents an attractive
intervention for cancer treatment. Many investigators have pointed their
therapeutic inquiries towards T cells as the major effector cells of the tumor
response, developing antibodies that can antagonize suppressive molecules and
cells, cytokines and molecules to agonize T cell effector functions and reverse
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tolerance and anergy, or adoptively transferring activated cells into the tumor
environment itself (291). Others have taken on a more holistic approach in
targeting cells or pathways of the innate immune response that enable the
efficacy of the adaptive response (292).
This section aims to provide current knowledge on immune therapies
utilized in the treatment of cancer, including immune checkpoint blockade,
stimulators of the innate immune response, and efforts to combine therapies
directed at components of the innate and adaptive immune arms. Studies
discussed will be broadly in multiple tumor models, but with special attention to
those currently used for bladder cancer.

1.3.1: Therapeutic Targeting of Immune Checkpoints

Inhibitory checkpoints. Immune checkpoints are biologically important for
maintaining self-tolerance and limiting bystander tissue damage during the nonspecific innate immune response and hyper-activated adaptive immune response
(293). However, these anti-inflammatory processes can be commandeered by
tumors to evade immune-mediated destruction. In the treatment of cancer,
immune checkpoint blockade removes these inhibitor signals to NK,
macrophage, and T cell (effector cell) activation and function, enabling antitumor
immune cells to overcome regulatory mechanisms established by tumors, and
eliminate them (294). Inhibitory checkpoints like CTLA-4, the PD-1/PD-L1 axis,
TIM-3, and LAG-3 all have different mechanisms to make immune cells,
particularly T cells, quiescent, and therefore different therapies have been
developed to address them.
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CTLA-4, as discussed previously, has very similar homology to CD28, and
therefore shares the same ligands CD80 (B7.1) and CD86 (B7.2), necessary for
APC-mediated co-stimulation and activation amplification of T cells (295).
However, CTLA-4 has over 100x more affinity for both CD80 and CD86, and its
engagement with either ligand down-modulates the amplitude of T cell
responses, typically at the site of T cell priming in secondary lymphoid organs
(261, 296, 297). Expression of CTLA-4 is upregulated upon T cell activation on
the cell surface and at the immunological synapse (298), and is thought to be
more predominantly expressed on CD4 T helper cells, insinuating that
heightened T cell responses seen with CTLA-4 inhibition are due to promoted
activity of CD4 T cells on other immune subsets (CD8 T cells) (299). CTLA-4
expressed on Tregs also has a role in attenuating the effector T cell response
(300). Therefore, blockade of CTLA-4 with inhibitory antibodies has been shown
to enhance tumor rejection by inhibiting Treg function and Treg killing (301, 302),
enhance CD28 co-stimulation and T cell activation, and thus expansion of tumor
antigen-specific CD8 T cells (303). It does this by blocking CTLA-4 competition
for costimulatory ligands by antagonistic antibody binding to the interaction
domain on B7 (304). Anti-CTLA4 therapy also leads to the expansion of effector
CD4 populations (305), as well as exhausted CD8 populations (306). In humans,
anti-CTLA-4 therapy with ipilimumab (307) antibody produced a 3-year survival
rate of 21% in metastatic melanoma patients (308), and similarly a 5-year
survival rate of 20% was observed patients treated with tremelimumab (antiCTLA-4 mAb) (309). Unfortunately, as anti-CLTA-4 therapy is effectively lowering
the activation threshold and taking the brakes off of effector T cells, many
patients experience immune-related adverse events while on therapy (310). This
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is also potentially due to CTLA4 blockade-associated TCR repertoire broadening
which increases T cell functional reactivity (311).
The PD-1/PD-L1/PD-L2 axis serves primarily to maintain tolerance and
dampen T cell responses in the periphery (312), and similar to CTLA-4, its
expression as both receptor and ligands is induced upon B and T cell activation,
and as a byproduct of the immune response on many cell types in the TME
(313). PD-L1 and PD-L2 are widely expressed on non-lymphoid tissues and
actively upregulated in response to inflammatory cytokines like IFNs (314).
Unlike CTLA-4, PD-1 signaling directly interferes with the TCR signaling cascade
to regulate T cell activation (315). Persistent PD-1 signaling also induces
metabolic restriction, inhibiting glycolysis while simultaneously promoting fattyacid oxidation (FAO) and lipid catabolism, perpetrating T cell exhaustion (316,
317). Blockade of PD-1 signaling can reinvigorate effector cells and antigenspecific T cells by preventing the attenuation of TCR signaling, effectively jumpstarting exhausted T cells to proliferate (318). It has also recently been shown to
reverse negative metabolic reprogramming induced by PD-1 signaling (319).
Because of the propensity of PD-1 ligands expressed in tumor tissue and by
immune cells of the tumor stroma, it has been suggested that the effectiveness of
PD-1 therapy is reliant on the bulk of effector cells to be already present in the
TME (320). Early large scale clinical trials with anti-PD-1 antibody Nivolumab
have shown successful antitumor responses in patients, with objective response
rates of 17%, 27%, and 31% in NSCLC, RCC, and melanoma, respectively.
However, exhausted T cells have a distinct epigenetic profile that can limit T cell
reinvigoration, and thus PD-1 blockade may not be sufficient to functionally
restore T cells once they meet a certain exhaustion threshold (321, 322).
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Other inhibitory checkpoints are currently being explored preclinically and
in clinical trials as the “next generation” of checkpoint blockade therapy.
Lymphocyte activation gene 3 (LAG-3) is highly homologous to the CD4 T cell
co-receptor, and as such its ligand is the MHC class II molecule (323); however
new work has found a potential additional ligand as LSECtin (324). As previously
mentioned, LAG-3 is expressed on T cells, B cells, NK cells, and DCs in
response to activation, and serves as a negative regulator of T cell expansion
and DC activation as it competitively binds with MHC II (325, 326). T cell
immunoglobulin and mucin-3 (TIM-3) is marker for exhaustion in combination
with other checkpoints, expressed on activated T cells, NK cells, Tregs, DCs, and
monocytes, and negatively regulates Th1 type immunity. TIM-3 functionally binds
to galectin-9 (265), PtdSer (327), HMGB1 (328), and CEACAM-1 (329) to
promote immune cell dysfunction and apoptosis by negatively regulating TCR
signaling, and other mechanisms not fully clarified (330, 331). VISTA, B7-H3, and
TIGIT all represent other recently identified immune inhibitory receptors that
negatively regulate T cell activity, and are currently being investigated further to
understand their mechanisms of action (299).

Co-stimulatory checkpoints. Immune activation is mostly regulated by two
major receptor families: the immunoglobulin-like (Ig) superfamily, consisting of
co-stimulatory receptors CD28 and inducible T cell co-stimulator (ICOS), and the
TNFR superfamily, consisting of co-stimulatory receptors OX40, CD27, 4-1BB,
CD40, and GITR (332, 333). A general theme in the function of these stimulatory
receptors, and potential antibodies that may be used to agonize them
therapeutically, is that the resulting effects will be 1) activation of APCs, 2)
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reduction in Treg suppressive activity and 3) co-stimulation of CD4 and CD8 T
cells and NK cells, based on the cells that express the receptor (334).
The Ig superfamily comprises receptors that express a variable
immunoglobulin-like domain that binds to cognate ligands expressed on APCs;
for ICOS, the ligand is B7H (335). ICOS is upregulated on activated T cells, B
cells, and ILC2 cells and serves to enhance type I and II immune responses, T reg
maintenance, TFH differentiation (294). It regulates the production of IL-4 (336),
antibody isotype switching (337). ICOS signals though PI3K/AKT signaling and
also enhances calcium signaling (PLC) (338), suggesting it has a role in cellular
metabolism, protein translation, and apoptosis (339). In preclinical studies,
agonist antibodies to ICOS have shown antitumor potency and activation of
effector immune responses similar to antagonistic blockade of its other Ig
superfamily inhibitory members (340). However, antagonist antibodies to ICOS
also show positive effects in dampening Treg functions (340). Studies are
ongoing, but much more needs to be learned about the dual effects of ICOS and
its ligand to better understand its therapeutic use in patients.
The TNFR family members are appealing candidates for targeted
therapies, with the greatest attention being laid on OX40 and 4-1BB. 4-1BB
(CD137) is an enhancer of T cell co-stimulation, through signaling of TRAF1 and
TRAF2 (341). 4-1BB or its ligand 4-1BBL are expressed on activated T cells, NK
cells, monocytes, DCs, and B cells. Ligation on T cells results in upregulation of
anti-apoptotic genes and protection from activation induced death, promoting the
differentiation of memory T cells (342). In preclinical trials, agonistic 4-1BB
antibody enhances antitumor T cell responses and enables tumor rejection (343),
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however in clinical studies in patients, there is evidence of serious immune
related adverse events, and so dosing, timing schedules, and combination
approaches are still under investigation (344). OX40 is present on activated T
cells, Tregs, NK cells, NKT cells, and neutrophils, and its ligand is expressed on
APCs and T cells as well. Its ligation has been shown to inhibit Treg suppression,
and sustain and enhance CD4 T cell responses, as well as CD4 and CD8 T cell
survival and memory generation (345, 346). It regulates survival signaling though
Bcl-2/Bcl-xL and also enhances PI3K/AKT signaling (347). Similar to 4-1BB,
preclinically OX40 agonist antibodies increase anti-tumor activity (348), and DCs
with enhanced OX40 expression can enhance tumor rejection in a CD8, CD4,
and NK T cell dependent manner (349). Therapeutic agonism of OX40 in patients
has not been completed on a large scale, but it has been shown to induce
proliferation of effector T cells and augment tumor-immune responses (350).
GITR, CD27, and CD40 and their ligands are expressed on T cells, B cells, NK
cells, APCs upon activation, and through their own signaling schemes likewise
are important for promoting T cell and NK cell activation and proliferation,
humoral immune response (CD40), APC maturation, inhibiting Treg function
(GITR), and generating T cell memory (CD27) (351-354). While proving to be
exciting new targets in the field of cancer therapy, the fundamental biology of
these molecules remains underdeveloped, and is being outpaced by clinical
investigations, so there is much still to be learned regarding their function and
signaling paths.

1.3.2: Innate Immune Stimulation
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Toll-Like Receptor Agonists. Immune checkpoint blockade and adoptive cell
transfer of antigen-specific T cells have owed their therapeutic success to the
improved function, recruitment, and activation of T cells, or more broadly, the
adaptive immune response. Historically, the best responders to these therapies
are patients with tumor subtypes that are highly CD8 T cell infiltrated, have
chemokine signatures and other indicators of chronic inflammation, have high
mutational burdens, and typically include high expression of immune inhibitory
factors such as PD-L1, IDO, or Tregs, among others. However, macrophages,
DCs, NK cells, and other cells of the innate immune system, via their roles in
antigen recognition, presentation, T cell co-stimulation and direct tumor cell
killing, are essential for the initiation, maintenance and programming of antitumor
immune reactions, making them attractive targets for therapeutic exploitation.
Toll-like receptor stimulation, as one of the best defined PRR pathways, can
serve as a key activator of an antitumor response, aimed at waking up the host
immune response when spontaneous T cell priming has not occurred (292).
Down regulation of antigen expression and suppression of APC
maturation and priming are some strategies that tumors have cultivated in order
to evade innate immune recognition. As previously discussed under the innate
immune response, TLRs expressed on immune cells are type I transmembrane
proteins that have fundamental roles in the detection of diverse microbial
signatures. TLRs 2, 4, 5, 6 detect proteins, peptidoglycans, lipids (LPS), and
bacterial flagellin extracellularly, while TLRs 3, 7, 8, 9 detect single-stranded or
double-stranded RNA, and CpG modification of DNA residues (CpG-ODN)
intracellularly (Table 1). Several ligands agonizing theses TLRs have already
been approved, and used in cancer therapy: TLR2/4 agonist BCG, TLR4 agonist
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monophosphoryl lipid A (MPL), and TLR7 agonist imiquimod (355-357). Others
such as TLR5 agonist Entolimod, and TLR7 agonist 852A are still being
investigated in preclinical and clinical trials (358, 359).
Focusing more on the Th1 immunity-inducing TLRs, nucleic acid sensing
TLRs (3,7,8,9) are relevant to cancer detection as they can recognize DAMPs
from cellular debris of necrotic or dying tumor cells (360). Upon ligand binding,
these TLRs induce signaling cascades through NF-kB and interferon regulatory
factors (IRFs) to promote the transcription of inflammatory cytokines and IFNs-I
(361). TLR7 agonist imiquimod has shown antitumor effects in basal cell
carcinoma, with more limited activity in melanoma and breast tumors (356, 362).
It is believed to aid in recruitment of tumor-infiltrating plasmacytoid DCs (pDCs)
and macrophages by cytokines TNF, IL-12, and IFN, leading to further
infiltration of helper T cells (363). Imiquimod is being further tested for use in
noninvasive bladder cancer (364) and as an adjuvant to cancer vaccines in
several solid tumors (365). Resiquimod, a dual TLR7/8 agonist, has been shown
to more potently induce cytokine expression than TLR7 therapy alone (366).
Clinical studies in skin tumors have shown improved recruitment of effector T
cells, antigen-specific CD4 T cell responses, and tumor cell elimination (367,
368). TLR9 ligation by unmethylated cytosine-guanosine (CpG) DNA induces
type I IFN production, activating DCs, NK cells, and tumor-specific CD8 T cells
and generating tumor regression (369). CpG ODNs (oligonucleotides) are
synthetic agonists of TLR9 which are most actively being explored in solid and
hematologic cancers as both monotherapies and adjuvants (370). CpG ODN and
TLR9 agonist SD-101 has demonstrated the ability to overcome tumor resistance
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to checkpoint blockade therapy and increase effector T cell infiltration in
preclinical studies (371); clinical trials in humans are ongoing. TLR3 stimulation
by recognition of double-stranded RNA dsRNA induces the secretion of type I
IFNs, similar to TLR9, but also can lead to direct activation of apoptosis of tumor
cells (372). In addition to stimulating TLR3, is activates RLR sensing, instigating
a two-pathway production of IFN-I (373). Poly(I:C) is a synthetic dsRNA that is
being explored preclinically and clinically in the treatment of many solid cancers,
including bladder cancer (373, 374). Poly(I:C), and derivatives of it have been
shown to inhibit tumor growth and promote tumor infiltration of activated immune
cells (375-377), however most of its uses and successes in patients are as an
adjuvant therapy (378).
Though not a TLR, STING PRR agonists are also being exploited in
cancer therapy. To review, like TLR9, cytosolic enzyme cyclic GMP-AMP
synthase (cGAS) senses foreign DNA within the cell cytosol and synthesizes
dinucleotide cyclic GMP-AMP (cGAMP) (379). cGAMP is then able to bind and
activate STING, initiating pro-inflammatory signaling that induces IFN-I
transcription and NF-kB mediated production of IL-6, IL-15, TNF, and IL-1 (380382). STING signaling is important for the generation of tumor-specific CD8 T cell
responses and tumor regression (383). STING agonistic cyclic dinucleotides
such as cyclic di-GMP and 2’3’-cGAMP are utilized in therapeutic investigation
because of their affinity, stability, and specificity for STING (384). Preclinical
studies have found that STING agonists can suppress cancer metastasis,
increase CD4 and CD8 T cell recruitment, and stimulate IL-12 production by
MDSCs, furthering the activation of inflammatory cells (385, 386). Initial clinical
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studies of STING agonist (DMXAA) in humans proved unsuccessful due to poor
CDN binding to STING (387), but new agonist structures are currently being
investigated in clinical trials alone and in combination with another
immunotherapy.
Recent studies have identified TLR expression on cancer cells
themselves, linking their expression with diseases progression, metastasis, and
shortened survival (388, 389). The potential dual agonistic and antagonistic role
in cancer inhibition or progression, as well as their potential serious adverse
effects, including cytokine storm, have drawn caution to the use of TLR
stimulants in immunotherapy (390). Despite some hesitancy, the use of TLR
agonists has shown definitive antitumor benefits by activating immune cells in the
TME, and inducing the expression of pro-inflammatory cytokines that facilitate
immune infiltration and inhibit oncogenic signaling in the tumor. In many cancers,
though TLR agonists show efficacy, more work needs to be performed to better
define their mechanisms of action to ensure confidence for their use in humans.

Cytokine therapy: Interferon-alpha. Interferons have a pleiotropic role in the
stimulation of antitumor immunity. As previously mentioned, almost all cells are
capable of producing and responding to IFN-I, however pDCs are able to secrete
higher levels of type I IFN than any other cell type. Often, type I IFN induction is
the product of stimulation of TLR, RLR, or STING signaling pathways. Activation
of IFN receptors leads to a multifaceted response including but not limited to:
promotion of NK cell function (391), support for DC maturation, migration, and
antigen presentation/priming to activate T cells (392), stimulating chemokine
production for immune recruitment (118-120), and direct cell killing through
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TRAIL-mediated apoptosis (393); but counter-productively, it can induce immune
suppressive enzymes such as IDO (394), and increase expression of PD-L1 on
stromal and cancer cells (395), contributing to tumor-immune evasion.
Preclinically, IFN-I production has been shown to be critical for CD8+ DC crosspresentation to CD8 T cells, generating antigen-specific immunity and tumor
rejection (396, 397). Exogenous IFN and IFN delivery to tumors by either
association with transferred monocytes or conjugation to antibodies resulted in
impeded growth and metastasis (398, 399). There is also evidence that the
production or delivery of IFN-I can help mitigate tumor-induced suppressive
immune cells (400), thereby overcoming some mechanisms of immune
avoidance. Although the process of immunoediting, in which tumors cycle
through elimination, equilibrium, and evasion with the immune response, can
produce mechanisms of resistance to immune-mediated tumor eradication, type I
IFNs intervene in all of these phases (401, 402).
In bladder cancer specifically, IFN has been investigated as a salvage
therapy in NMIBC after BCG failure due to its anti-proliferative activity on tumor
cells. Both IFN and IFN have also shown to inhibit tumor growth by inhibiting
angiogenesis and expression of VEGF and basic fibroblast growth factor (FGF)
in human xenograft orthotopic mouse models of bladder cancer (403-405).
However, when using recombinant IFN protein in experimental strategies,
antitumor-related results were not durable due to unsustainable IFN levels
(406). To overcome these limitations, intravesical gene delivery of IFNα through
the use of adenoviral encoding IFNα (Ad-IFNα/Syn3, i.e. Instiladrin) was
developed (407), and early clinical trials have shown its safety and efficacy in
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treating BCG Unresponsive NMIBC (66, 67, 408). Clinical studies evaluating the
use of intravesical Ad-IFNα/Syn3 in the bladder are ongoing. IFNs-I direct and
indirect effects on tumor cells, the TME, and the immune system have been
described broadly in multiple cancer models. Because IFN’s mechanisms are
diverse, its precise role in the immune response to cancer has only begun to be
understood in bladder cancer, and they could be distinct between tumor types.
Elucidating IFN’s immune-mediated antitumor mechanism in bladder cancer is
therefore critical for interpreting patient response, identifying effective
combination therapies, and improving the treatment of bladder cancer.

1.3.3: Current Status of the Therapeutic Utility of Single and Combination
Immune Therapy

Immune checkpoints. Remarkable advances in immunotherapy treatment for
cancer have occurred in recent years. Approaches aimed at co-activating
different tumor inhibitory pathways with immunotherapy, radiotherapy, targeted
molecular therapy, and chemotherapy are widely used. Most immune
checkpoints are non-redundant, leaving the possibility of combination checkpoint
blockade, or antagonist/agonist approaches open. Based on understanding of
how CTLA-4 and PD-1 act to attenuate T cell activity (activation and effector
function, respectively), it is believed that anti-CTLA-4 and anti-PD-1 therapies
can act at different stages of the cancer-immune response (87). Single agent
checkpoint inhibitors have seen successful activity in advanced and metastatic
malignancies, as discussed previously, with roughly 20% survival rates (anti-
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CTLA-4) and 30% response rates (anti-PD-1) in patients with melanoma, nonsmall cell lung cancer, and renal carcinoma (308, 409-412). However, treatment
of patients with combination checkpoint inhibitors produced longer median
progression-free survival (PFR) rates than either therapy alone (413, 414). Other
inhibitors and stimulators of checkpoints, notably TIM-3, LAG-3, ICOS, 4-1BB,
and OX40 among others, are currently being investigated as single agents, and
in combination with anti-PD-1/PD-L1/CTLA-4 therapies (415). Progress that has
been achieved through monotherapies is notable, however certain aspects of the
TME may limit tumor responses, for example by upregulation of additional
checkpoint molecules to limit single agent treatment efficacy (294). Targeting
immune checkpoints improves patient median survival and also can provide longterm durable responses, and combinatory immunotherapies may lead the pack in
increasing the number of patients who continue to see clinical benefit over time.

Innate immune stimulators. For poorly immune-infiltrated tumors, providing
inflammatory signals to facilitate recruitment of activated effector cells is
beneficial in fighting tumor progression. This can be seen with single agent
recombinant viral vector therapy, exogenous cytokines, and TLR agonists, used
to incite chemokine production and an inflammatory response (416). However,
therapeutic potential of PRR agonists have focused on their adjuvant use in
activating an immune response, and most successes in cancer have come in
combination therapy with checkpoint inhibition, adoptive cell transfer, or cancer
vaccines, rather than as a single agent. Treatment with exogenous cytokines can
promote cytotoxic activity of effector CD8 T cells and NK cells, and differentiation
of CD4 T cells into T helpers; however, some cytokines can expand Treg
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populations and promote nonspecific activation of immune cells with associated
toxicities (417). To limit these adverse effects, current clinical trials are
investigating modified inflammatory cytokines like IFN-I, IL-15, and IL-2 in
combination with checkpoint inhibitors, utilizing more targeted delivery tactics
rather than systemic approaches. Immunotherapeutic strategies that
simultaneously target the innate and adaptive immune response are suggested
to reduce immune tolerance, and are effective in eliminating large tumors (418,
419). The combination of TLR agonists and checkpoint blockade is thought to
augment T cell activation and to potentially overcome resistance to checkpoint
blockade by priming APCs to enhance the adaptive immune component (361).
Indeed, combination of TLR9 agonist CMP-001 with anti-PD-1 Ab
pembrolizumab was reported to reverse PD-1 inhibition resistance with no
maximum tolerated dose (420). Clinical studies of the combination of TLR
agonists with checkpoint inhibitors have also shown increased levels of APCs in
the TME and suppression of head and neck cancers (421). Many trials are
ongoing with the combined use of TLR3, 4, 7, 8, 9 and STING agonists with antiPD-1 antibody, anti-CTLA4 antibody, or a combination of all three (361, 377). To
move forward in improving patient responses, care providers need to have an
arsenal of weapons to meet cancer at every turn. Mechanistically speaking, the
ability to use an innate stimulator to jump start a lagging immune response but
coincidentally may increase tumor evasion mechanisms, followed by an adaptive
targeted therapy like checkpoint inhibition to combat the Stimulator’s induced
evasion is akin to cutting off cancer’s support legs.

1.3.4: Summary
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Humans are equipped with the exquisite defensive tools of the immune system to
fight off pathogens, cellular dysregulations, and cancer. Despite our intrinsic
innate and adaptive mechanisms, malignancies like cancer have evolved
strategies to avoid our immune system and continue surviving. Therapeutic
intervention with drugs designed to reverse immune-suppressive mechanisms
has proved to be a successful venture in tumor inhibition. Many therapies
antagonizing immune inhibitory checkpoints, or agonizing intrinsic innate immune
activation or stimulatory checkpoints are either approved or being investigated for
use in patients today. It’s important to keep in mind, as these therapies are
designed to increase effector cell responsiveness and inhibit suppressive
mechanisms that adverse reactions and tissue damage due to highly stimulated
cytotoxic cells will occur. Ultimately, the balance of harm versus benefit must be
constantly monitored to ensure patient safety, treatment efficacy, and clinical
ethics.
For bladder cancer, BCG therapy in NMIBC already capitalizes on TLR
stimulation to produce antitumor efficacy, though there is room for improvement
for patients who exhibit disease progression, recurrence or no response to BCG.
For more aggressive tumors, the approved use of checkpoint inhibitors in bladder
cancer has demonstrated improved overall response rates for locally advanced
and metastatic disease, and is continually being studied in combination settings
(422-424). The use of Ad-IFNα therapy for BCG Unresponsive patients may be
able to fill the need of an alternative immune stimulatory treatment, inducing TLR
recognition and endogenous IFN-I production, to control and treat NMIBC.
However, one of the qualms of BCG is the incomplete understanding of its
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mechanism of action; as IFN is a pleotropic cytokine, elucidating its specific
immune-mediated antitumor mechanism is therefore critical for interpreting
patient response, identifying effective combination therapies, and improving the
treatment of bladder cancer.
I hypothesized that IFN specifically induced recruitment and activation of
immune cells into NMIBC tumors, leading to more robust antitumor responses
alone and in combination with checkpoint blockade therapy. First looking at
patients to determine the validity of these questions, I found that treatment with
Ad-IFNα therapy induced expression of T cell markers and checkpoint markers
within NMIBC tumors, and a plethora of inflammatory cytokines compared to
before treatment. This finding encouraged further investigation into the MB49 and
BBN murine bladder cancer models to determine which immune cells were most
crucial in the IFN-mediated antitumor response, and if and how they were
recruited to the tumor. The patient data also encouraged finding the utility of
combination immunotherapy with IFN and checkpoint blockade (anti-PD-1)
treatment on mouse bladder cancer tumors, to see if there were synergistic
effects on tumor inhibition and survival. The results are detailed in the next
chapters.
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Chapter 2: Effects of Ad-IFN Therapy in Patients with NMIBC

This work is based upon “Inhibition of urothelial carcinoma through targeted type
I interferon-mediated immune activation” by Plote, D, Choi, W, Mokkapati M,
Sundi, D, Ferguson, J, Duplisea, J, Parker, N, Yla-Herttuala, S, McConkey, D,
Schluns, K, Dinney, C. 2019. Oncoimmunology; presented with permission from
Oncoimmunology.

2.1: Introduction

Non–muscle-invasive bladder cancer (NMIBC) comprises ~70% of
diagnosed urothelial carcinomas (UC) (9). Although not immediately lifethreatening, they have a propensity to recur and progress. Intravesical therapy,
mainly in the form of Bacillus Calmette-Guerin (BCG), is administered to prevent
recurrence, delay progression, and provide for bladder preservation to avoid the
quality of life issues that accompany radical cystectomy (9, 425). Despite its
success as frontline immunotherapy, not all patients respond to BCG, and of
those who do respond, over half will relapse with BCG Unresponsive NMIBC (68,
69, 426). Unfortunately, no effective second-line therapy for BCG Unresponsive
NMIBC exists (68-70, 425). Interferon alpha (IFNα) is a pleiotropic cytokine that
inhibits tumor growth directly as well as indirectly through activation of the
immune system. These multifaceted anti-tumor properties make IFNα a
promising alternative therapy for UC. IFNα monotherapy for NMIBC was
previously studied demonstrating good tolerability and dose-related clinical
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effectiveness following BCG failure; however, its response durability was
insufficient (406). With standard intravesical therapy, patients are unable to retain
the instilled cytokine for more than 1- to 2 hours, limiting local tumor exposure.
To overcome these limitations, intravesical gene delivery of IFNα through the use
of adenoviral encoding IFNα (Ad-IFNα/Syn3, i.e. Instiladrin) was developed and
early clinical trials have shown its safety and efficacy in treating BCG
Unresponsive NMIBC (66, 67, 408). Clinical studies evaluating the use of
intravesical Ad-IFNα/Syn3 in the bladder are ongoing (66, 67, 408).
Despite the clinical efficacy that has been achieved with Ad-IFNα/Syn3 in
BCG unresponsive patients, its mechanisms of action are still not well defined in
UC. It has been previously demonstrated that IFNα gene therapy inhibits the
growth of human tumor xenografts by an anti-angiogenic effect and tumor
necrosis factor-related apoptosis ligand (TRAIL)-mediated cytotoxicity (393, 403405, 407). However, since these previous preclinical data were generated in
studies of nude mice, the immune mechanisms underlying the anti-tumor activity
of IFNα in UC have not been elucidated. It has been well described that a type I
IFN response indirectly induces a cascade of inflammatory cytokines and
chemokines to encourage recruitment of effector immune cells to the site of host
distress (115). It also directly stimulates immune cells that can then further
activate the adaptive cellular response, including memory CD8 T cells. I
hypothesize that Ad-IFNα/Syn3 utilizes this induction of cytokines and increased
immune cell recruitment and tumor infiltration to bestow its antitumor effects in
patients with NMIBC.
In this portion of the study, I sought to identify what changes occurred in
patients and their tumors before and after treatment with Ad-IFNα/Syn3. I wanted
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to determine if patient tumors were more highly infiltrated with effector cells after
treatment, and if there was a correlated relationship with the presence of
inflammatory cytokines. Using RNA from eight Phase I Trial patients biopsied
before and after treatment with Ad-IFNα/Syn3, I found that only 2/8 patients
showed robust increases in expression of several T cell related genes, though
four other patients displayed increase in at least one T cell marker gene. This
response rate was further confirmed by IHC staining of the same patient
specimens, in that 1/5 patients with banked tissue samples showed an increase
in CD3+ cells following treatment with Ad-IFNα/Syn3. Utilizing urine samples from
39 Phase II Trial patients, I identified if treatment with Ad-IFNα/Syn3 affected the
expression of inflammatory cytokines and chemokines present in the urine, as a
marker of the immune response, and if the presence of these cytokines was
correlated with patient response to therapy, or clinical response (CR). I found that
compared to pre-treatment samples, Ad-IFNα/Syn3 significantly increased the
urinary levels of IFN and CXCL10, while also increasing TRAIL, CCL2, and IL-6
four days after instillation with Ad-IFNα/Syn3. The increase in urinary IL-6 was
also correlated with patient CR.
The potential for a non-invasive biomarker detection of bladder cancer,
and treatment response is a vigorously sought-after discovery. Urine is already
used in urological practice for bladder cancer screening, as a secondary
measure of malignant cell presence (cytology) (5). Utilizing urine cellular and
molecular analysis as a predictive or prognostic marker of patient response to
therapy represents an ideal non-invasive procedure for both patients and
physicians. Previous studies have demonstrated that cytokines levels in urine
can be used to determine response to BCG therapy, experimentally (82);
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however, there is no definitive evidence of cellular biomarkers of therapeutic
response in bladder cancer, or as a measure of response to Ad-IFNα/Syn3. I
investigated the potential use of flow cytometry on urine samples to identify
therapeutically-driven changes in both immune cell populations, and epithelial
cell populations. Preliminary results revealed that it is possible to identify T cell
populations and epithelial population in urine by flow cytometry, and that further
investigation into more functional markers is possible. Utilizing CyTOF analysis
may also prove to be a greater biomarker identification tool for future analysis of
patient samples.

2.2: Results

2.2.1: Ad-IFNα Therapy in BCG-Unresponsive NMIBC Patients Induces an
IFN-I Response in the Bladder and Increases Expression of T cell and
Checkpoint Markers
Because our previous preclinical data and Phase I trials has provided evidence
that localized, sustained IFN could be therapeutically beneficial to BCGUnresponsive NMIBC patients (66, 407, 408), a Phase II trial with intravesical
Ad-IFNα/Syn3 was conducted in 39 patients (67). To confirm that localized AdIFNα/Syn3 treatment induced a sustained IFN-I phenotype, we measured
cytokine concentrations in patient urines. Ad-IFNα/Syn3 instilled on Day 1
significantly increased urine levels of IFNα2, CXCL10 on Day 4, with additional
increasing trends in TRAIL, CCL2, IL-6, and G-CSF on Day 4. Significant
increases in IFNα2, CXCL10 were still present by Day 12 (Figure 4A).
Interestingly, the correlation of increased urinary IFNα2 and IL-6 levels from
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Day4:Day1 (D4:D1) was significant for 13 patients who exhibited a complete
response (CR) to Ad-IFNα/Syn3 therapy, and not significant for patients deemed
“non-responders” (NR, 26 of 39 patients) (Figure 4B). There was also positive
correlation for increased G-CSF levels in relation to increased IFNα2 and CR at
Day 4, but it did not reach statistical significance (Figure 4B). There was no
positive correlation with any other cytokine from Day12:Day1 (D12:D1) in relation
to increased IFNα2 and CR (Figure 5). Interestingly, there are significant positive
correlations of IFNα2 level vs. CXCL10 and TRAIL on D4:D1 for 26 of 26 patients
who did not achieve CR, and IFNα2 vs. CXCL10, CCL2, and IL-6 on D12:D1
from 24 of 26 of these patients (Figure 5). This may be related to a prolonged
inflammatory response that may have deleterious effects on the patient and
tumor as noted in other tumor models (427), but is an area for further
investigation in NMIBC. Whole transcriptome RNAseq was conducted with
matched pre-treatment and post-treatment tissue specimens from 8 patients with
BCG-unresponsive NMIBC, treated with Ad-IFNα/Syn3 in the Phase I trials (66,
408). Gene expression of PD-L1, CTLA-4, and several T cell markers were
markedly increased in two of eight (25%) matched tumor pairs following
treatment with Ad-IFNα/Syn3 (Figure 4C). Less dramatic upregulation of one or
more immune biomarkers was evident in 4 of the 6 additional tumors. In addition,
histology sections from 5 of the 8 tissue samples were also stained for CD3+ T
cells. IHC analysis of these tumors showed an increase in CD3 T cells, localized
in the tumor stroma, after treatment with Ad-IFNα/Syn3 in 1 of 5 samples (Figure
4D), and undetectable changes in the CD3+ populations in the other 4 samples
(data not shown), exemplifying IFNα’s ability to enhance intratumoral T cells with
variability in patients.
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More thorough molecular analysis of the 8 matched pre- and post- AdIFNα/Syn3 treated patient tumor specimens from Figure 4C showed similar
trends to the Phase II urine samples of cytokine levels, as well as other published
knowledge of IFN-I induced gene signaling (Figure 6). Many of the IFN response
and immune cell mediated cytotoxicity genes such as CXCL10, CCL5, CCL4,
CCL2, PRF1, CD8A, and NFATC1 were increased in at least 4 of the 8 patient
samples post- Ad-IFNα, mimicking characteristics of a Th1-type immune
response. These results are also seen in the MB49 mouse tumor model, and will
be discussed more in Chapter 4. Mirroring upregulation seen in urine samples, 4
of 8 patients also had an increase in IL-6 gene expression. Interestingly, there
was decreased tumor expression of genes related to fatty acid catabolism
(FASN, ACLY, ACACA), amino acid transport, and VEGFA post-treatment,
potentially indicating a role for IFN to decrease metabolic pathways in tumor
inhibition. However, despite the heterogeneity of tumor response, none of the 8
patients analyzed achieved CR at 12 months.
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Figure 4: Effects of intravesical Ad-IFNα/Syn3 therapy on T cells and
immune biomarkers in patients. A) Log2 observed concentration (Day 1 preAd-IFNα therapy [D1], Day 4 post- Ad-IFNα therapy [D4] or Day 12 post- [D12])
of levels for cytokines indicated. Significant p-value (one way ANOVA, multiple
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comparisons) **p<0.01 and ***p<0.001 comparing D1:D4 and D1:D12 (Error
bars: mean ± SEM; n=39). B) Spearman correlation between log2 expression of
IFNα2 levels and respective cytokine indicated from ratio of Day 4 post AdIFNα/Syn3 to Day 1 pre-treatment in 39 patient urines. Rank coefficient r > 0.5
indicates a positive correlation with IFNα2. Yellow boxes indicate significant p
value (Two tailed) *p<0.05, ***p<0.001. CR=Complete Response patients;
NR=Non-Responder patients. C) RNA from macrodissected matched tumors
collected before or after Ad-IFNα therapy was analyzed by whole transcriptome
RNAseq (Ion Torrent Ampliseq platform). Top panel: ratio of gene expression in
posttreatment to pretreatment specimens. Note: gene expression increased
significantly in two of the eight tumor pairs. Red = increased expression, green =
decreased expression. Bottom panel: heat map displaying differential gene
expression in each tumor pair. D) Immunohistochemistry staining of CD3 + cells in
a patient tumor (Tumor 1 (C)), pre- and 3 months post-treatment with one dose of
Ad-IFNα/Syn3. Scale bar = 200 µm.
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Figure 5: Correlation of inflammatory cytokines measured in patient urine
12 days after Ad-IFNα/Syn3 treatment. A) Spearman correlation between log2
expression of IFNα2 levels and respective cytokine indicated from ratio of Day 12
post Ad-IFNα/Syn3 to Day 1 pre-treatment in 39 patient urines. Rank coefficient r
> 0.5 indicates a positive correlation with IFNα2. Yellow boxes indicate significant
p value (Two tailed) *p<0.05, ***p<0.001. CR=Complete Response patients;
NR=Non-Responder patients.
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Figure 6: Ad-IFNα/Syn3 treatment increases gene expression associated
with Th1 type anti-tumor immunity and decreases expression of metabolic
markers. Heatmap illustrating normalized (log2) gene expression patterns from
patients treated with Ad-IFNα/Syn3. RNA was isolated from FFPE tumor
specimens from Phase I and Ib trials of Instiladrin (Ad-IFNα/Syn3). Whole
transcriptome RNA sequencing was performed using the Ion Torrent
AmpliseqRNA platform analyzed using AmpliSeqRNA plugin with the Torrent Suit
Software, and visualized with the Broad Institute’s Morpheus software. Samples
were hierarchical clustered according to averaged one minus pearson
correlation.
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2.2.2: Utilizing Urine as a Non-invasive Diagnostic and Prognostic
Resource in the Analysis of the UC Immune and Epithelial Landscape after
treatment with Ad-IFNα Therapy
Previous work in UC has utilized urine as a biomarker medium for identifying
NMIBC patient responses to BCG therapy, but it was focused on voided levels of
inflammatory cytokines rather than measuring changes in the intra-bladder cell
populations (82). Recent work has identified the use of urine-derived
lymphocytes (UDLs) as a liquid biopsy tool for mapping the TME and identifying
patients with actionable targets, like high PD-1 expression, in cases of MIBC
(428). To this end, I hypothesized that similar strategies from these studies could
be applied for NMIBC patients treated with Ad-IFN: to utilize flow cytometry to
identify immune cells and epithelial cells in voided urine, with the goal of
identifying markers of patient response to therapy, and the potential identification
of candidates for combination therapy strategies. Using urine voided from
patients about to undergo standard TURBT for preliminary investigation, I found
that viable immune cells and epithelial cells could be analyzed (Figure 7A). As
expected, cytokeratin+ cells expressed higher levels of PD-L1 than CD45+ cells
(Figure 7B), following the results seen by many other groups. Contrary to the T
cell focused study in MIBC, this flow analysis showed that myeloid cell
populations as well as lymphoid cells could be easily distinguished within CD45+
cells (Figure 7C), which is relevant to the mechanisms of action of IFN-I.
Interestingly, of the lymphocyte (SSC/FSC) population, roughly 50% were
TCR+CD8-, indicating a large proportion of CD4 T cells, with only about 20% of
CD8+ lymphocytes by comparison (Figure 7D). These results serve as a proof of
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concept that urine can be used to measure the immune response in NMIBC
patients. Further investigation into identifying functional aspects of these urinary
cells, like activation status and checkpoint expression, is being performed using
CyTOF analysis in order to develop a more comprehensive diagnostic protocol
for liquid biopsy and detection of patient response.
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Figure 7: Patient urine can be utilized to prospectively identify immune and
epithelial responses to IFN therapy. Analysis of one representative urine
sample from a patient about to undergo routine TURBT. Flow cytometry plots
depicting A) percentage of CD45+ immune cells versus pan-Cytokeratin positive
epithelial cells, which were more PD-L1 positive than the CD45+ cells (B). C)
Forward scatter and side scatter immune cell classification of CD45+ population
based on size resolution. D) Frequencies of TCR+CD8-, TCR+CD8+, and
TCR-CD8- cells in the urine sample, gated from CD45+ lymphocyte cells.
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2.3: Summary and Discussion

There is an unmet need for effective alternative treatment options for
patients who undergo BCG treatment, but unfortunately exhibit tumor recurrence,
progression, or no response, and wish to preserve their bladder (avoid
cystectomy). Type I IFNs are known to stimulate innate immune cell activation,
enhancing recruitment of other inflammatory and effector cells, and to maintain
and regulate these cells’ functions. It’s immune influencing actions, along with
IFN-I’s ability to directly kill cells through TRAIL and caspase mediated apoptosis
make the use of IFN-I effective in cancer therapy, and attractive for BCG
unresponsive bladder cancer patients.
In this chapter, I report that the use of Ad-IFNα/Syn3 therapy in BCG
unresponsive NMIBC patients does induce expression of immune markers within
tumors, and incites secretion of inflammatory cytokines and chemokines that may
be used to encourage immune recruitment and tumor infiltration. Analyzing tumor
specimens from Phase I Trial patients pre- and post-treatment with AdIFNα/Syn3 showed increased RNA gene expression and IHC protein expression
of T cell markers (CD3, CD4, CD8) in about 25% of patients after instillation with
Ad-IFNα/Syn3. Delving deeper into the transcriptional changes in patient tumors
comparing before and after treatment, I also found increased expression of
cytokine and chemokine genes related to IFN-I response, increased expression
of immune cell cytotoxicity genes, and decreased expression of angiogenic and
metabolic genes related to fatty acid synthesis and amino acid transport.
Likewise mirroring the established effects of IFN-I from literature and the results
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seen with RNAseq here, I report that Ad-IFNα/Syn3 treatment increased
inflammatory cytokine levels in patient urines from the Phase II Trial, most
dramatically CXCL10, TRAIL, CCL2, G-CSF, and IL-6. Unexpectedly, I identified
that the increase seen in IL-6 post-therapy was positively correlated with patient
CR, inciting the need for further investigation into the role that IL-6 may play in an
IFN-mediated antitumor response. This will be further addressed in Chapter 3.
Angiogenesis has long been recognized as a major hallmark of cancer
progression and its induction can lead to tumor invasion and progression. IFN-I
pleiotropically affects multiple immune cell types, and can directly inhibit tumor
growth by decreasing tumor vasculature, which has been previously shown in my
group’s IFN gene therapy work (403). Recent reports show that antiangiogenic
therapy, such as VEGF/VEGFR2 inhibitors, can up-regulate PD-L1 mediated
immunosuppression as a strategy for immune escape (429). The use of
antiangiogenic therapy combined with immune checkpoint blockade has been
shown to promote higher lymphocyte infiltration and activity in several tumor
models (429), and is currently being investigated further in clinical trials. The
regulation of metabolic genes by IFN-I induction is an area that is currently under
investigation. UC cells rely on glycolysis-dependent metabolism as the main
energy source for oncogenesis, overexpressing genes such as GLUT1, HK2, and
LDHA/B to generate products of the TCA cycle (430). Bladder cancer also
increases expression of fatty acid synthesis metabolic genes in order to store
surplus energy generated (431). Here I show that Ad-IFNα/Syn3 treatment
downregulates the expression of lipid synthesis genes FASN, ACACA and ACLY,
and amino acid transporters SNAT1 and SNAT2, potentially contributing to tumor
inhibition. The role of IFN-I and angiogenesis and tumor cell and immune cell
77

metabolism will be discussed more in depth in Chapter 4 and the global
discussion in Chapter 5.
I think that Ad-IFNα/Syn3 treatment in a subset of patients (25-30%) is
effective in preventing recurrence when i) patient tumors are initially immune
infiltrated (by APCs), so that they can further incite an inflammatory and adaptive
response, and when ii) Ad-IFNα is able to stimulate viral nucleic acid sensors
(TLRs/STING), in addition to secreted TNF and IL-1, to increase production of
IL-6. IL-6 then acts as a master regulator of immune cell recruitment, activation,
expansion, and differentiation, and therefore promotes inhibition tumor growth by
immune activity and surveillance (to be discussed more in depth in Chapter 3).
However, a major aspect in patient response is if they had localized, lower
staged tumors and had a thorough and complete TURBT prior to instillation with
Ad-IFNα/Syn3. As evident from molecular profiling, histopathology, and diverging
clonality, tumors are extremely heterogeneous, leading to greatly varying patient
response. Response to therapy may be related to baseline immune infiltrate or
tumor mutational status, if they have lost or mutated expression of IFN genes or
other immune response genes, but more critical to the determination of response
is the initial staging of patient tumors; that roughly 30% of patients are
inaccurately staged (understaged) at the time of their TURBT, and so are
recommended inappropriate therapeutic strategies (44, 432).
Urine may also serve as a future liquid biopsy medium in NMIBC, to
identify patients who respond to therapy or who may be candidates for
combination immunotherapy, as I tested the possibility of immune and epithelial
cell identification and stratification from fresh patient urines. These data suggest
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that the use of Ad-IFNα/Syn3 therapy can potentiate immune-driven antitumor
responses and tumor inhibition in a subset of BCG unresponsive NMIBCs. The
finding that increased expression of T cell markers was coupled with increased
expression of inhibitory checkpoint genes also encourages the future testing and
use of immune checkpoint blockade and Ad-IFNα combination therapy in UC
treatment.
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Chapter 3: Interferon-alpha Activation inhibits growth of Murine Urothelial
Carcinoma

This work is based upon “Inhibition of urothelial carcinoma through targeted type
I interferon-mediated immune activation” by Plote, D, Choi, W, Mokkapati M,
Sundi, D, Ferguson, J, Duplisea, J, Parker, N, Yla-Herttuala, S, McConkey, D,
Schluns, K, Dinney, C. 2019. Oncoimmunology; presented with permission.

3.1: Introduction

Type I interferons (IFN-I), are produced by multiple cell types following the
stimulation of PRRs. Upon receptor activation, IFNs-I like interferon-alpha (IFNα)
and interferon-beta (IFNβ) elicit many immunostimulatory effects including
promotion of antigen processing, presentation, and recognition by professional
antigen-presenting cells, and production of cytokines and chemokines, which in
turn recruit and activate a cytotoxic T cell response against the tumor (91, 115).
As previously mentioned, IFN-I can intervene during all stages of immunoediting,
protecting the host against onconeogenesis and aiding the immune response to
control existing tumors (282, 433, 434). To this point, studies have shown that
absence of Ifnar1 encourages cellular transformation of embryonic fibroblasts
(435), and can increase tumor burden in carcinogen-treated mice (436).
Furthermore, many cancers have developed strategies to interfere with IFN
actions, downregulating expression of STAT proteins and interferon regulatory
factors and sensing genes (IRFs and ISGs) to inhibit IFN signaling and promote
tumor progression and metastasis (437-439). However, restoration of IFN
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signaling rescues immunosurveillance and an antitumor phenotype (397),
underlining its crucial role in the anti-tumor immune response.
Innate immune activation is critical to then further stimulate the antigenspecific effector cell response. IFN-I activated CD8+ DCs are necessary to
cross-prime tumor-specific CD8 T cells in vivo (397, 440). Preclinical studies in
immune-poor melanoma showed that an IFN-I response induced by TLR3
agonist poly(I:C) (polyinosinic:polycytidylic acid), a synthetic dsRNA that triggers
PRR activation on APCs, inhibited tumor growth and increased survival alone
and in combination with anti-PD-1 mAb checkpoint blockade (375). In this model,
the effectiveness of poly(I:C) was particularly reliant on interferon-gamma
positive (IFNγ+) CD8 T and NK cells (375). Further, robust tumor infiltration of NK
cells and cytotoxic T cells correlates with spontaneous IFN-I production and good
prognosis in melanoma patients (441, 442). IFNs-I also support the
differentiation of monocytes into mature macrophages, and promote
macrophage cytotoxicity and phagocytosis (121, 122). With the numerous
targets and pathways stimulated by IFN along with the variations in tumor
immune landscape, the mechanisms of IFN’s actions could be distinct between
tumor types. Because of the diversity of IFN’s mechanisms in regulating the
immune response and tumor control, elucidating IFN’s immune-mediated
antitumor mechanism in bladder cancer is critical for interpreting patient
response, identifying effective combination therapies, and improving the
treatment of bladder cancer. I hypothesize that type I IFN enhances the
activation and recruitment of effector immune cells in non-invasive bladder
cancer, leading to robust IFN-driven antitumor responses.
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In this portion of the study, I sought to identify the importance of specific
immune cell populations in the IFN-driven antitumor response in bladder cancer,
and the mechanisms by which IFN-I recruited cells to the TME. To elucidate the
immune mechanisms underlying IFN-I’s antitumor activity in UC, I utilized local
injection of the TLR3 agonist poly(I:C) into MB49 tumors in syngeneic C57BL/6
mice. Indeed, I found that poly(I:C) induces an IFN-I response, inhibits tumor
growth, and increases immune cells in murine MB49 tumors, but the antitumor
activity was not specifically reliant on any one immune cell type, unlike the
studies performed in melanoma (375). Interestingly however, there was an
important anti-tumor role for IFN-I induced IL-6. I also investigated the effects of
lentiviral-mediated IFN (LV-IFN) in the BBN-induced orthotopic mouse model
of non-invasive bladder cancer and found LV-IFN significantly prolongs animal
survival in comparison to lentiviral-empty vector controls (LV-CTL), and increases
the frequency of intratumoral NK cells and CD8 T cells compared to control
treated groups.

3.2: Results

3.2.1: Type I IFN Activation by Poly(I:C) Impairs MB49 Bladder Cancer
Growth
To determine how local induction of IFN-I impacts tumor growth in a murine
model of bladder cancer, MB49 bladder tumor cells were implanted
subcutaneously into syngeneic wildtype (WT) mice, followed by peritumoral
injections of established tumors with either poly(I:C) (100 µg) or PBS every three

82

days; changes in tumor growth were monitored over time (Figure 8A). MB49
cells were chosen owing to characteristics reminiscent of non-muscle invasive,
non-metastatic UC (443). Treatment with poly(I:C) delayed MB49 tumor growth
and significantly improved overall survival (Figure 8A, B). The antitumor effect of
poly(I:C) was mediated through IFNα signaling as poly(I:C) did not induce tumor
regression in IFNAR-/- mice (Figure 8C). Poly(I:C)-mediated tumor regression is
likely mediated in part through direct effects of IFN-I as murine IFNα increased
MB49 cell death in-vitro at doses over 100 IU/mL (Figure 8D). For reference, one
dose of poly(I:C) (100 µg) induced an average ~400 pg/mL of intratumoral IFNα,
and showed clearance from the serum in 24 hours (Figure 9A, B). Similar to the
observed effects with Ad-IFNα/Syn3 in human urine and tumors and in immunepoor melanoma (Figure 4A, C)(375), poly(I:C) treatment of MB49 tumors also
led to an induction of IFN-I responsive genes IRF7 and PD-L1 compared with
PBS-treated controls, as determined by RT-PCR (Figure 8E). Furthermore, the
increase in IRF7 expression significantly correlated with the up-regulation of
CD274 (PD-L1) gene expression across all tumor samples (Figure 8E). These
data show that poly(I:C) inhibits MB49 tumor growth and prolongs survival in an
IFNAR-dependent manner, suggesting important roles for IFNα. These data also
confirm in the MB49 model that IFNα has direct anti-tumor action, and that IFN-I
induces PD-L1 expression, as previously reported (444). Other murine UC cell
lines BBN975, UPPL1541 and UPPL1595 were also used the evaluate the in
vivo response to poly(I:C); however these tumor models exhibited spontaneous
regression in PBS-treated controls, or inconsistent growth patterns per replicate,
and were not deemed as viable tumor growth models (Figure 9C-E).
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Figure 8: Poly(I:C) Treatment impairs MB49 tumor growth while
upregulating PD-L1 expression on tumors. A) Tumor growth of subcutaneous
MB49 tumors treated peritumorally with PBS (closed circles) or poly(I:C) (open
square) beginning 7 days post-tumor implantation and continuing every 3 days.
B) Kaplan-Meier analysis showing survival of mice from A. C) MB49 tumor
growth curves of poly(I:C) or PBS-treated mice in WT or interferon alpha receptor
knockout (IFNAR-/-) mice. D) AnnexinV/PI staining for early (Annexin+PI-) and
late (Annexin+PI+) stage cell apoptosis of MB49 cells treated in vitro with
increasing doses of murine IFNα. E) Correlation of relative gene expression for
CD274 and IRF7 in control and poly(I:C) treated MB49 samples determined by
qRT-PCR. Error bars indicate mean ± SEM; n=5 mice per group in tumor
growth/survival and n=3 for in vitro. *p<0.05, ***p<0.001 with Student’s t test or
Log-Rank test (Kaplan-Meier).
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Figure 9: In vivo effects of poly(I:C) on IFN and tumor growth in BBN and
UPPL bladder tumor models. A,B) Average concentration (pg/mL) of IFNα in
MB49 tumors (A) and mouse serum (B) following one peritumoral injection of
poly(I:C). C-E) Tumor growth curves of poly(I:C) or PBS treated mice in with
either BBN975 (C), UPPL1541 (D), or UPPL1595 (E) tumors. Error bars indicate
mean ± SEM.
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3.2.2: Poly(I:C) Activates Intratumoral Innate and Adaptive Immune Cells
To investigate how poly(I:C) impacts intratumoral immune responses, we
examined established MB49 tumors for gene expression and immune cell
infiltration 24 hours after the prior treatment (day 14) with peritumoral poly(I:C) as
described. Poly(I:C) significantly induced the expression of IFN-I regulated gene
CXCL10, with other trending gene expression increases in IRF7 and the effector
cytokines TNFA and PRF1 (perforin) (Figure 10A). We also observed a
significant increase in the percentage of CD8 T cells and NK cell populations and
decrease in percentage in CD4 T cells in tumor infiltrates (Figure 10B).
Additionally, there was a consistent increase in Ly6G+ cells and accompanying
decrease in Ly6C+Ly6G- (Ly6Chi) and Ly6C-Ly6G- (Ly6Clo) populations, though
these changes were not statistically significant (Figure 10B, C), demonstrating
that poly(I:C) alters the composition of intratumoral CD11b+ myeloid cell subsets.
The CD8+ T cells in the poly(I:C)-treated tumors showed a trend in increased
expression of IFNγ (Figure 10D), which was not statistically significant. This
increased IFNγ may be due to an exhausted CD8+ T cell phenotype caused by
the IFN-I induced PD-L1 expression in the tumors (Figure 8E). We could also
observe similar effects in poly I:C-mediated changes in T cells in tumor tissue
sections. After two treatments of poly(I:C) (i.e. day 11) the total numbers of
intratumoral CD8+ T cells increased while CD4 T cells decreased (Figure 10E).
While these changes were not statistically significant, there was a significant
decrease in the ratio of CD4:CD8 T cells compared with PBS-treated control
mice (Figure 10F). Altogether, these findings suggest poly(I:C) promotes
immune cell recruitment and/or expansion.
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Though inconsistent for tumor growth studies, UPPL1541 and UPPL1595
tumors were analyzed for their immune infiltration with poly(I:C) treatment as
compared with PBS- treated controls. Mixed effects of poly(I:C) were observed in
UPPL1541 tumors, whereby poly(I:C) increased the percentage of total
intratumoral CD45+ cells, CD11b+Ly6G+/lo and decreased the
CD11b+Ly6ChiLy6G- population similar to MB49, but T cells were not affected. In
UPPL1595 tumors, which showed minimal growth inhibition from poly(I:C)
(Figure 9), the CD45+ population decreased with poly(I:C) treatment; however,
there were increases in the CD8 T cells, NK cells, and CD11b+Ly6G+
populations, similar to MB49 (Figure 11A, B). The inconsistent tumor growth
kinetics of both UPPL tumors despite both tumor lines exhibiting similar
molecular subtypes and mutations (445) may be a factor in their immune infiltrate
differences, and led us to believe these models needed to be further investigated
before use in our study.
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Figure 10: Induction of Type I IFN by poly(I:C) enhances immune cell
infiltration and activation. A) Relative gene expression of immune genes from
whole tumors treated with PBS or poly(I:C); Error bars indicate mean ± SEM;
n=4. B) Percentage of tumor infiltrating immune cells in poly(I:C)-treated tumors
compared to PBS- treated controls at day 14, n=4. C) Flow cytometry plot
depicting frequencies of Ly6G+, Ly6C+, and Ly6G-Ly6C- cells in a mouse from
each group in (B) analysis, gated from CD45+CD11b+CD11c- cells. D)
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Percentage of ex-vivo CD3 stimulated IFNγ+ CD8 T cells from PBS or poly(I:C)
treated MB49 tumors at day 14 post-implantation. E) Immunofluorescent staining
of tumor-infiltrating CD8+ (red) and CD4+ (green) cells in PBS- or poly(I:C)treated tumors after 2 treatments at day 11. Image representative of 3 tumor
samples per treatment group. Scale bar = 200μm. F) Ratio of CD4:CD8 T cells
calculated from tumors in (E); n=3 per group. *p<0.05, **p<0.01 with Student’s t
test.
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Figure 11: Poly(I:C) effects on immune cell infiltration in UPPL bladder
tumor models. A) Percentage of tumor infiltrating immune cells in poly(I:C)treated tumors compared to PBS-treated controls in UPPL1595 tumor model B)
Percentage of tumor infiltrating immune cells in poly(I:C)-treated tumors
compared to PBS-treated controls in UPPL1541 tumor model. All results from
Day 14 tumors. Error bars indicate mean ± SEM; n=5 per group. *p<0.05,
**p<0.01 with Student’s t test.
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3.2.3: IL-6 is important for Poly(I:C) Anti-tumor Efficacy, But No Specific
Immune Cell Population is Required
To understand the role of individual immune cell types in MB49 tumor
progression and IFN-I-mediated antitumor responses, we examined tumor
inhibition in mice deficient in various innate and adaptive cells. MB49 tumor
growth in PBS-treated RAG-/- mice was increased in compared to PBS-treated
WT mice; however, tumor growth was equivalent in poly(I:C)-treated RAG-/- and
WT mice (Figure 12A). Similarly, depletion of T cell populations with anti-Thy1.2
or anti-CD8 mAbs led to increased tumor growth in PBS-treated mice, but did not
affect tumor growth in poly(I:C)-treated mice (Figure 12A). Altogether, these data
indicate that while adaptive immune cells moderate growth of MB49 tumors in
untreated controls, they were not critical for the poly(I:C)-mediated antitumor
response. While IFNs can stimulate NK cells and an IFNγ+ NK cell antitumor
response (375), in our MB49 model, depletion of NK cells led to a reduction in
tumor growth (Figure 12A) suggesting NK cells are pro-tumor in an untreated
MB49 model, and that they do not play a critical role in poly(I:C)-mediated antitumor activity. To address the role of neutrophilic MDSCs and monocytes/
macrophages, efficacy of poly(I:C) was examined in mice depleted of Ly6G+ or
CSFR1+ cells, respectively. Whereas depletion with αLy6G mAb had no effect on
tumor growth in either PBS- or poly(I:C)-treated mice, depletion of CSFR1+ cells
led to significant tumor regression in control mice but not (poly)I:C-treated mice.
These results suggest that in this tumor model, CSFR1+ tumor-associated
macrophages, but not Ly6G+ cells have anti-tumor activity but are not critical to
the poly(I:C)-mediated anti-tumor response. Interestingly, we observed a modest
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abscopal effect following the treatment of the primary MB49 tumor with poly(I:C)
(Figure 12B) that was abrogated when mice were depleted of CD8+ T cells
(Figure 12C). Collectively, these findings suggest that T cell adaptive immunity is
enhanced by poly(I:C) treatment but is not crucial for its antitumor effect.
We also examined the roles for IL-15 and inducible nitric oxide synthase
(iNOS) in the IFN-I response due to the central role for IL-15 in driving IFNmediated T cell and NK cell responses (446), and the reported use of iNOS as an
anti-tumor effector produced by Ly6G+ neutrophils (447). In IL-15 receptor α
deficient mice (IL15Rα-/-), both PBS and poly(I:C) treatments had similar antitumor effects as in WT mice indicating a minimal role for IL-15 in the poly(I:C)
response (Figure 13A). Drug-mediated inhibition of iNOS by N-iminoethyl-llysine (L-NIL) had no effect on tumor growth when animals were treated with
poly(I:C) however, in PBS-treated mice, inhibition of iNOS reduced tumor growth
(Figure 13B). Because activation of innate cells can lead to production of IL-12,
a cytokine important in the Th1 immune response and IFNγ induction (112, 448),
we looked at the gene expression of both IL-12 isoforms and their heterodimeric
receptor and found that poly(I:C) does significantly increase IL-12p40 and IL12Rb1 expression within tumors (Figure 13C). Collectively these results suggest
that the regulation of IL-15 or iNOS by IFN-I are not critical to the antitumor
response of poly(I:C) in this model system, but there may be a role for IL-12
influencing the IFN-I induced Th1 response.
Due to the positive correlation of IL-6 with IFN and patient response
(Figure 1), we investigated the effect of IL-6 in MB49 tumor growth. The antitumor benefit of poly(I:C) was significantly inhibited in IL-6 knockout mice (IL-
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6KO), and survival of poly(I:C) treated IL-6KO mice was also significantly
decreased as compared to poly(I:C) treated WT mice. (Figure 12D, E). In
addition, poly(I:C) upregulated IL-6 protein as poly(I:C)-treated MB49 tumors had
higher levels of IL-6 per mg of tumor as compared to PBS-treated controls,
though this increase was not statistically significant (Figure 12F). As in earlier
experiments (Figure 10B, C), poly(I:C) altered the myeloid cell landscape by
significantly increasing the frequency of Ly6G+ cells and decreasing Ly6Chi and
Ly6Clo cells within the tumors (Figure 12G). Interestingly, these changes in the
myeloid cell landscape did not occur in tumors present in the IL-6KO (Figure
12G). Among tumor lymphocytes, the changes in NK and T cells observed in
poly(I:C)-treated tumors in WT mice were still intact in IL-6KO mice, though the
poly(I:C)-mediated increase in CD8 and decrease in CD4 T cells was slightly
impaired in IL-6KO (Figure 12H). We also examined additional parameters of
lymphocyte activation in the poly(I:C)-treated WT and IL-6KO mice. Within
secondary lymphoid tissues, poly(I:C) increased the frequency of Ki-67+ NK cells
and CD8 T cells in spleens and draining lymph nodes (dLN) but not in tumors,
which was abrogated in IL-6KO mice (Figure 14 A, B, data not shown).
Similarly, there was an increased frequency of Granzyme B+ CD8 T cells in dLN
with poly(I:C) treatment that was impaired in IL-6KO mice (Figure 14C). Overall,
the anti-tumor response elicited by IFN-I likely represents the collective activity of
multiple cellular components of the adaptive and innate immune response
pathways.
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Figure 12: Anti-tumor efficacy of poly(I:C) relies on IL-6 signaling and
multiple immune subtypes. A) Growth of MB49 tumors treated peritumorally
with PBS or poly(I:C) in RAG-/- mice or WT mice depleted of specific immune
cell populations with the indicated Ab or given control Ig. Anti-Thy1.2 mAb was
used to deplete T cells and anti-CSFR1 mAb was used to deplete monocytes
and macrophages; n=5 per group. B) Tumor growth of primary and secondary
MB49 tumors in WT mice. Primary (“Established”) tumors were treated
peritumorally with either PBS or poly(I:C) beginning 7 days post-implantation.
Secondary (“Contralateral”) tumors were implanted 4 days after the primary
tumors. Arrow indicates beginning of treatment. C) Tumor growth of the
contralateral tumor similar to (B) in CD8 depleted mice. D) Growth of MB49
tumors treated peritumorally with PBS or poly(I:C) in IL-6 knockout (IL-6KO) or
WT mice. E) Kaplan-Meier analysis of survival of mice from D; n=5. F) Average
concentration of IL-6 (pg/mL) per tumor weight (mg) in MB49 tumors from Day 14
tumors treated with either poly(I:C) or PBS; n=5 per group. G,H) Frequency
(percentage) of Ly6G+, Ly6Chi, and Ly6Clo cells (G) and frequency of NK, CD4,
CD8 T cells from MB49 tumors of WT and IL-6KO mice treated with PBS or
poly(I:C) among gated CD45+CD11b+ cells and CD45+ cells, respectively; n=5.
Error bars indicate mean ± SEM; *p<0.05, **p<0.01, ***p<0.001, ****p<0.0001
with Student’s t test.
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Figure 13: Anti-tumor efficacy of Poly(I:C) is not mediated by IL-15 or iNOS.
A) MB49 tumor growth curves of poly(I:C) or PBS treated mice in WT or IL-15
receptor alpha knockout mice (IL15Rα-/-). B) MB49 tumor growth of mice treated
with iNOS inhibitor L-NIL in combination with peritumoral PBS or poly(I:C). For all
groups, n=5. Error bars indicate mean ± SEM. C) Log2 gene expression of IL-12
subunits and receptor subunits from MB49 tumors after 3 treatments of PBS or
poly(I:C); n=4 per treatment group, error bars indicate mean ± SEM. *p<0.05 with
Student’s t test.
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Figure 14: Poly (I:C)-mediated lymphocyte activation is impaired in the
absence of IL-6. A,B) Percentage of Ki-67+ immune cells in either spleen (A) or
tumor draining lymph node (dLN) (B) of poly(I:C)-treated WT and IL-6KO mice
compared to PBS- treated respective controls at day 14, gated from CD45+ cells;
spleen n=5, dLN n=3. D) Percentage of GZMB+CD44+ CD8 T cells in spleen and
tumor dLN of poly(I:C)-treated WT and IL-6KO mice compared to PBS- treated
respective controls at day 14, gated from CD45+CD8+ cells; spleen n=5, dLN
n=3. Error bars indicated mean ± SEM. *p<0.05, ***p<0.001 with Student’s t test.
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3.2.4: LV-IFN promotes survival and increased intratumoral immune
effector cells in BBN-induced murine bladder tumors
To determine how local production of IFN-I by viral-mediated intravesicle
instillation impacts tumor inhibition and immune cell responses in the bladder, I
examined animal survival and tumor-immune infiltrate in the N-butyl-N-(4hydroxybutyl)-nitrosamine (BBN) carcinogen-induced murine orthotopic bladder
cancer model (Figure 15). Following 60 days of BBN treatment, in which mice
were deemed to have non-invasive tumors or CIS (Figure 15A), mice were
intravesically instilled weekly with LV-IFN or LV-CTL. Differences in tumor
growth were difficult to monitor, as ultrasound imaging was not sensitive enough
to detect weekly changes; however, treatment with LV-IFN significantly
prolonged survival in comparison to LV-CTL (Figure 15B). Investigating the
effect of LV-IFN on the immune infiltrate of BBN-induced tumors, I observed an
increase in the frequency of CD8 T cells in both lentiviral-vector treated groups
as compared to PBS controls, but this increase was not statistically significant
(Figure 15C). Unlike the MB49 model, there was no increase in Ly6G+ cells and
accompanying decrease Ly6C+ populations (Figure 15C), suggesting that LVIFN doesn’t preferentially induce a Ly6G+ cell response like poly(I:C).
Altogether, these findings suggest that like poly(I:C) in MB49 tumors, LV-IFN
treatment promotes survival and immune cell recruitment and/or expansion in the
BBN-induced tumor model. However, it is important to keep in mind that the
inherent differences between the MB49 and BBN-induced tumors brought on by
their origins, such as their mutational burden and pathology, may be linked to the
diversity in their immune landscapes and responses to IFN-I, as seen here.
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Figure 15: LV-IFN improves survival and increases intratumoral immune
cells in BBN-carcinogen induced bladder cancer. A) Experimental strategy for
development of BBN-induced bladder cancer mouse model. After 2 months, mice
began intravesical instillation with lentiviral-control vector (LV-Control) or
lentiviral-IFN vector (LV-IFN). B) Kaplan-Meier analysis of survival of mice
treated with either LV-Control of LC-IFN. C) Frequency (percentage) of NK,
CD4, and CD8 T cells from the SSC/FSC CD45+ lymphocyte population,
frequency of CD11b+ cells from the SSC/FSC myeloid designated population,
and Ly6G+ and Ly6C+ cells among gated CD11b+ population from bladder of
BBN-tumor induced mice treated with LV-Control or LV-IFN; n=5. Error bars
indicate mean ± SEM; *p<0.05, **p<0.01, ***p<0.001 with Student’s t test or LogRank test; These experiments were performed in part by Dr. Sharada Mokkapati.
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3.3: Summary and Discussion

The use of type I IFN as a cancer therapy has had mixed successes due
to its route of administration and short half-life. Despite early therapeutic
shortcomings, IFN-I has been shown to have direct tumor killing ability by the
induction of TRAIL and apoptosis signaling, and it can incite an inflammatory
response, including maturation and activation of innate and adaptive immune
cells, promoting their migration to the tumor. Because of the variety of IFN’s
mechanisms in controlling tumor growth and the immune response across
different tumor types, determining IFN’s immune-mediated antitumor
mechanism in bladder cancer is critical for interpreting patient response,
identifying effective combination therapies, and improving patient outcomes.
In this chapter, I examined the immune mechanisms behind IFN-Imediated anti-tumor responses in murine models of UC. I found that IFN-I
induction by poly(I:C) in MB49 tumors inhibits tumor growth, increases longevity,
and activates both the innate and adaptive immune systems. Poly(I:C) increased
the intratumoral frequencies of CD8, NK, and Ly6G+ cells, and decreased the
frequencies of CD4 and Ly6C+Ly6G- cells, but it’s antitumor efficacy was found to
not be dependent on any one of these individual cell types. The poly(I:C)
mediated tumor inhibition was, however, found to be dependent on functioning
IL-6 signaling, which was necessary for higher levels of intratumoral Ly6G+ and
CD8 cells, and proliferation and activation of NK cells and CD8 cells in secondary
lymphoid organs. This IL-6 dependence mirrors the positive correlation of IL-6
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urinary cytokine expression with patient response (CR) to Ad-IFNα/Syn3 therapy.
I also found that LV-IFN similarly prolonged survival and increased intratumoral
T cell and NK cell populations in the BBN-induced bladder cancer mouse model.
Treatment of MB49, BBN, and UPPL tumors with poly(I:C) or LV-IFN
resulted in an IFN-I induced infiltration of highly diverse immune populations
representing a multifaceted pro-inflammatory anti-tumor phenotype, contrary to
the defined dependence of tumor-inhibitory poly(I:C) on specific immune subsets
in studies performed in melanoma (18). Previous studies in experimental bladder
cancer have focused on the necessity of the T cell infiltration for an anti-tumor
response, and thus have relied on T cell checkpoint targeted immunotherapy
(443, 449, 450). However, the importance of both lymphoid and myeloid cell
types in the anti-tumor response in my MB49 studies indicates that focusing on a
single subset of effector cells may limit the insights to be gained.
I also found an important role for IL-6 signaling in the type I IFN-driven
MB49 tumor inhibition as well as in patients treated with Ad-IFNα/Syn3. IL-6 has
been shown to have a dichotic role, acting as both a pro-inflammatory and an
anti-inflammatory cytokine, in cancer as well as autoimmune diseases, providing
an activation signal to immune cells that left unchecked has the potential to
produce deleterious effects (451). As previously mentioned, IL-6 regulates innate
and adaptive immune defense in a pro-inflammatory capacity by inducing the
acute phase response, hematopoiesis (granulopoiesis), B cell differentiation
and antibody production, and recruitment of neutrophils and other immune
cells by promoting increased expression of trafficking chemokines CCL2,
CXCL5, CXCL6 and adhesion molecules CD62L, ICAM-1, and VCAM-1(130,

101

131, 139). It also promotes the activation and expansion of T cells, and
differentiation of CD4 T cells into i) TFH cells to aid in B cell antibody switching
and ii) pro-inflammatory Th17 T cells, and can suppress inducible CD4 Treg
formation and function (132-134, 139). Anti-inflammatory effects of IL-6 include
a role in wound healing and liver regeneration (137), and regulation of the
production of pro-inflammatory cytokines TNF, GM-CSF, IFN, MIP-2 in acute
inflammation to prevent deleterious immunopathology and promote
inflammatory resolution (138, 452).
In the MB49 model treated with poly(I:C) and in NMIBC patients treated
with Ad-IFN, I believe IL-6 is the master key in regulating the multifocal
immune cell anti-tumor response by increasing chemokine production for
immune recruitment, particularly the Ly6G + cell recruitment, and increasing NK
and T cell proliferation and activation, summarized in Figure 16. Backing this
conclusion, it has been shown that IL6-/- neutrophils have impaired respiratory
burst and degranulation, and also have impaired leukocyte apoptosis, affecting
the transition into adaptive immunity (453). IL-6 also increases CD8 cytotoxic
activity in vitro (134), supporting my observation that IL6-/- mice had decreased
GZMB+ CD8 T cells in the draining lymph node. There are many other effects of
IL-6 on immune cells that I did not thoroughly investigate here, such as the
propensity and role of CD4 Th17 and Treg cells in the MB49 model, and how IL-6
may affect macrophage activity and monocyte differentiation which was just
touched upon by CSFR1 depletion in WT mice (Figure 12A). I would speculate
that IL-6 driven differentiation and activation of Th17 cells and macrophages also
contributes to the IFN-I antitumor response in bladder cancer by further
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promoting neutrophil recruitment, T cell priming, and pro-inflammatory cytokine
production (454). The potential link of IL-6 to type I IFN-driven anti-tumor
responses in both murine models and in patients sparks the need for further
investigation of the role of this cytokine in IFN-I treated bladder cancer.
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Figure 16: Suspected role of IL-6 signaling in UC. Stimulated by inflammatory
cytokines, TLR signaling and stress, IL-6 is produced by almost all stromal and
immune cells. It goes on to activate STAT3 signaling and regulate T cell
differentiation (promotes CD4 Th17, inhibits CD4 Treg), proliferation, and
activation (GRZB+). IL-6 is also important in the recruitment of innate and
adaptive immune cells through induction of the acute phase response (secretion
of inflammatory cytokines) and stimulation of chemokine production from stromal
cells. I show that IL-6 signaling is needed to increase (Ki67+) NK cell proliferation
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in secondary lymphoid tissues. Not depicted here: IL-6 also controls B cell
survival, expansion and maturation (Ab production), but I did not examine the B
cell compartment in MB49/BBN tumors.
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Chapter 4: Combination Therapy of Interferon-alpha Activation with T-Cell
Checkpoint Modulation Prolongs Survival

This work is based upon “Inhibition of urothelial carcinoma through targeted type
I interferon-mediated immune activation” by Plote, D, Choi, W, Mokkapati M,
Sundi, D, Ferguson, J, Duplisea, J, Parker, N, Yla-Herttuala, S, McConkey, D,
Schluns, K, Dinney, C. 2019. Oncoimmunology; presented with permission from
Oncoimmunology.

4.1: Introduction

In addition to its roles in promotion of DC, macrophage, T cell, and NK cell
maturation, migration/taxis, and function (118-120, 391, 392), and direct cell
killing through TRAIL-mediated apoptosis (393), IFNα has been shown to
increase programmed death ligand-1 (PD-L1) and programmed cell death
protein-1 (PD-1) expression on tumor and immune cell subsets (395, 444).
Induction of PD-L1 and PD-1 has led to adaptive immune resistance by
promoting T cell exhaustion and immune evasion (244, 289, 395, 444). This
consequence may decrease the effectiveness of IFNα as a monotherapy, but
suggests that IFNα use in combination with immune checkpoint blockade may
lead to improved therapeutic outcomes. Use of anti-CTLA-4 and anti-PD-1/PD-L1
checkpoint blockade therapies have produced clinical responses and tumor
regression across many solid and hematologic cancers, often with durable or
indefinite results, by increasing absolute lymphocyte counts and T cell activation,
inducing expression of ICOS, and depleting Treg populations (90, 455). However,
106

refractory disease and acquired resistance mechanisms via immunoediting are
major problems of checkpoint blockade therapy (455).
Indeed, acquired resistance to PD-1/PD-L1 blockade is associated with
loss of genes encoding IFN receptor-associated Janus kinases, JAK1 and JAK2
(288, 456). Additionally, non-responders to checkpoint inhibitors such as antiCytotoxic T-Lymphocyte Antigen-4 (anti-CTLA-4) possess tumors with codeletions of IFNα and IFNβ genes on chromosome 9p21 and defects in IFN
pathway genes (288). These findings highlight the potential exploitable
relationship between not only PD-1/PD-L1 and IFNs, but other checkpoint
molecules as well. I hypothesize that though IFN-I induces expression of immune
evasion markers like the PD-1/PD-L1 axis, combined use of IFN and anti-PD-1
checkpoint inhibition therapy will synergistically increase the antitumor effects
against bladder cancer seen with IFN alone, via increases in immune
recruitment and activation and decreased tumor growth, improving clinical
benefit.
Understanding the relationship between IFNα and immune checkpoint
inhibition is important for interpreting immunotherapy resistance and improving
the treatment of UC and other solid tumors. In this portion of the study, to test
therapeutic synergism, I utilized local poly(I:C) administration in combination with
systemic anti-PD-1 mAb therapy in C57BL/6 mice with MB49 tumors. I found that
their combined use reduced tumor burden comparably to single-agent poly(I:C)
treated mice, but combination treatment significantly prolonged animal survival.
However, no significant difference was found in the intratumoral immune cell
populations between single agent and combination treated tumor groups.
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Investigating the differences between either poly(I:C) or anti-PD-1 mAb alone,
and combination treatment of MB49 tumors on a molecular level, combination
treatment comparatively decreased tumor vasculature and angiogenesis, and
increased expression of genes associated with metabolism, extracellular matrix
organization, and ERK/MAPK signaling. I also compared the molecular changes
seen in PBS-, poly(I:C)-, anti-PD-1 mAb-, and combination-treated MB49 tumors
to pre- and post- Ad-IFN treated patient tumor samples (from Figure 6), and
found that signaling pathway genes associated with poly(I:C) treatment, such as
IFN response and cytotoxicity are similarly upregulated, and metabolic pathway
genes are similarly downregulated to those in patients post-Ad-IFN treatment,
but not with anti-PD-1 or combination treatments.

4.2: Results

4.2.1: Combination Treatment with Anti-PD-1 mAb and Poly(I:C) Reduces
Tumor Burden and Prolongs Survival
Given that IFN-I signaling induces expression of checkpoint markers such as PDL1 (Figure 4, 8) which may lead to decreased effector T cell function (244, 289,
395, 444), we reasoned that therapeutic blockade of the PD-1/PD-L1 pathway
could further enhance the anti-tumor efficacy of poly(I:C). Subcutaneous MB49
tumor-bearing mice were treated with poly(I:C) and a PD-1–blocking mAb either
as monotherapies or in combination (Figure 17A). Tumor growth was measured
overtime until mice became moribund. Treatment with both single-agent poly(I:C)
and combination therapy [poly(I:C) with anti-PD-1 mAb] significantly repressed
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tumor growth compared with anti-PD-1 mAb alone and IgG/PBS-treated controls
(Figure 17B). However, we observed no significant difference in tumor growth
inhibition between poly(I:C) monotherapy and combination therapy. Nonetheless,
combination therapy significantly prolonged survival compared with poly(I:C)
alone (Figure 17C) demonstrating IFN-I can work with checkpoint blockade for
enhanced efficacy. In 16 day-old MB49 tumors treated with either single agent or
combination therapy, combination treatment significantly increased the level of
intratumoral Ly6G+ cells in comparison to poly(I:C) alone, which may contribute
to the difference in survival, but there was no significant difference between the
CD8, CD4, NK, and Ly6C+ immune cell populations between poly(I:C) and
combination treatment groups (Figure 18). However, this observed result was
only from one experimental analysis, and would need to be consistently repeated
for a more definitive conclusion.
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Figure 17: Blockade of PD-1/PD-L1 pathway reduces tumor burden and
prolongs survival in poly(I:C) treated mice. A) Experimental strategy for
combination therapy for s.c. engrafted MB49 tumors for peritumoral poly(I:C) and
anti-PD-1 mAb (i.p.). B) Averaged tumor growth of mice treated with either single
agent poly(I:C) or anti-PD-1 mAb, poly(I:C) plus anti-PD-1 mAb, or control IgG
plus PBS or control observation. C) Kaplan-Meier analysis of survival of mice
from C. Error bars indicate mean ± SEM, n=10; *p<0.05, **p<0.01, ***p<0.001
with Student’s t test or Log-Rank test; Graphs representative of 3 separate trials.
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Figure 18: Poly(I:C) and anti-PD-1 mAb combination therapy increases
intratumoral Ly6G+ cells in MB49 tumors as compared to poly(I:C) alone.
Percentage of tumor infiltrating immune cells in poly(I:C)-, anti-PD-1 mAb-, and
poly(I:C) + anti-PD-1 mAb- treated MB49 tumors compared to IgG + PBStreated control MB49 tumors at Day 16. CD8, CD4, and NK cells are gated from
CD45+ SSC/FSC designated lymphocytes; Ly6G and Ly6Chi cells are gated
from lineage negative (TCR-CD19-NK1.1-), CD11b+ cells. aPD1, anti PD-1
mAb; Combo, combination poly(I:C) + anti-PD-1 mAb treatment. Error bars
indicate mean ± SEM, n=5; *p<0.05, **p<0.01, ***p<0.001 with Student’s t test.
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4.2.2: Combination Treatment Induces MAPK Signaling, Metabolic
Pathways, and Reorganization of Tumor Microenvironment
To examine potential molecular changes between treatment groups,
comprehensive gene expression analysis was performed via RNA sequencing
and GSEA on total mRNA collected from day 17 tumors treated with PBS,
poly(I:C), anti-PD-1 mAb, or in combination. GSEA of the RNAseq data from the
poly(I:C), anti-PD-1 mAb, and the combination showed enrichment in viral stress
response, IFN signaling, cytokine signaling pathways, and innate immune
response in comparison to control tumors (Table 2). However, the single agent
anti-PD-1 mAb as well as the combination treatment also enriched pathways
promoting cell migration, differentiation, proliferation, and survival through MAPK,
MEK/ERK and AKT signaling (Table 2). Combination treatment up-regulated
additional pathways related to collagen formation, extracellular matrix formation,
and cell-cell signaling (Table 2). Comparing the poly(I:C) and combination
treated groups to each other, metabolic pathways for glucokinase regulation and
fatty acid oxidation (FAO) and synthesis were enriched in the combination group
(data not shown).
Looking more closely at effects on individual genes, we found numerous
genes related to IFN pathway signaling (Figure 19A), as well as adaptive and
innate effector cell cytotoxicity such as Granzyme B (GZMB) were significantly
increased in the poly(I:C) treated group, and more modestly increased in the antiPD-1 mAb and combination treated groups, in comparison to control IgG/PBS
treated tumors (Figure 19A, B). As expected, there were also increases in gene
expression for immune suppressive molecules in poly(I:C), anti-PD-1 mAb, and
combination treated mice, including ARG1 and ARG2 (Arginase 1 and 2), IDO,
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and CD274 (PD-L1) (data not shown). Exploring the GSEA-identified upregulated
metabolic pathways, we found poly(I:C) induced expression of glucose
transporter GLUT1, and all treatment groups increased expression of glycolysis
enzymes HK2 and GCK in comparison to PBS/IgG control (Figure 19A, B).
Interestingly, while poly(I:C) decreased tumor expression of genes related to fatty
acid catabolism and synthesis such as FASN, ACACA, and ACLY in comparison
to PBS control, anti-PD-1 mAb and combination treatment significantly rescued
their expression (Figure 19A, B). We also observed increased MAPK signaling
genes in all treated groups in comparison to control, and decreased expression
of VEGF, MMP9, and EGFR. Similar trends in gene expression were also
observed in the 8 matched pre- and post- Ad-IFNα/Syn3 treated patient tumor
specimens from Figure 6, despite none of the patients reaching CR. To further
investigate the decreased expression of angiogenesis markers seen in the
RNAseq of MB49 tumors treated with poly(I:C), anti-PD-1 mAb, or combination,
we performed IHC staining of CD31 on tumors from each treatment group taken
at their end point (day 38) (Figure 19C). Poly(I:C) alone and in combination with
anti-PD-1 mAb significantly decreased microvessel density (MVD) compared to
control PBS/IgG treated tumors by ~50% (Figure 19D). Thus, while IFN-I has
significant anti-tumor action, combination therapy with checkpoint blockade
activates additional pathways regulating the increased stromal influx and
reorganization of ECM, inhibition of angiogenesis, glycolysis and fatty acid
catabolism, and increased MAPK/ERK/AKT signaling that may be related to
prolonged survival.
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Table 2: Summary of the Reactome Gene sets enriched in treatment groups: Name, Process Category,
Description, Number of genes involved, NES
Treatment

Reactome Name

poly(I:C)

Process
category

Activation of genes by ATF4

signaling

PERK regulated gene
expression

signaling

Interferon γ signaling

immune

Toll receptor cascades
Class I MHC mediated
antigen
processing/presentation
TRAF6 mediated IRF7
activation

immune

Description
transcription factor;
response to ER stress,
PERK signaling
integrated stress
response and protein
folding

Number
of genes

NES`

21

1.89

24

1.79

42

1.75

109

1.65

221

1.59

immune

type II IFN signaling
TLR stimulated immune
signaling
innate and adaptive
immune recognition of
antigen

immune

viral, IFN response

20

1.58

pathway

secretory pathway for
synthesized proteins

52

1.58

ER Phagosome pathway
Latent infection of homo
sapiens with mycobacterium
tuberculosis
Antigen processing cross
presentation
Antigen presentation, folding,
assembly, and peptide
loading of Class I MHC

pathway

cell death pathway

53

1.56

immune

innate immune effectors

30

1.55

immune

antigen presentation

65

1.55

immune

antigen presentation

15

1.54

*

Innate immune system

immune

201

1.68/1.58

*

immune

37

1.63/1.68

*

IL-1 signaling
Nucleotide binding domain
Leucine rich repeat
containing receptor NLR
signaling pathways

innate immune signaling
damage associated
molecular pattern
(DAMP), inflammatory
signaling

42

1.59/1.54

*

NOD1/2 signaling pathway

immune

NOD-like receptor
signaling, viral response
NOD-like receptors for
antigen recognition,
inflammatory signaling

29

+

Interferon signaling

immune

interferon signaling

121

+

Interferon α,β signaling
Cytokine signaling in Immune
system
Antiviral mechanism by IFN
stimulated genes
Negative regulators of RIG-I
MDA5 signaling

immune

type I IFN signaling

43

immune

224

immune

cytokine signaling
antiviral stress response
through IFN
viral recognition receptor
sensing

28

1.58/1.71
1.88/1.77
/1.7
1.77/1.65
/1.62
1.75/1.77
/1.52
1.72/1.99
/1.97
1.69/1.58
/1.55

Interaction between L1 and
ankyrins

developm
ent

cell adhesion molecules

20

1.67

Signaling by ILs

immune

inflammatory signaling

102

1.57

SEMA4D in semaphorin
signaling

signaling

CD100 binding to CD72
to activate immune cells

28

1.55

Trans golgi network vesicle
budding

+
+
+

α-PD-1 mAb

signaling

immune
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62

developm
ent
developm
ent

#

Myogenesis
Platelet aggregation plug
formation
JNK, C-JUN Kinases
phosphorylation and
activation mediated by
activated human TAK1
MAP Kinase activation in TLR
cascade
SEMA4D induced cell
migration and growth cone
collapse

#

SHC1 events in ERBB4
signaling

signaling

#

MAPK targets/Nuclear events
mediated by MAP Kinases

signaling

#

Signaling by PDGF

signaling

Pre notch processing in golgi

signaling
developm
ent

poly(I:C) + αPD-1 mAb

Muscle contraction
Activation of chaperone
genes by XBP1S

signaling
signaling

signaling

Collagen formation
Extracellular matrix
organization

signaling
developm
ent
developm
ent

Gap junction trafficking

signaling

Chondroitin sulfate dermatan
sulfate metabolism
Chondroitin sulfate
biosynthesis

metabolic
metabolic

ERK/MAPK targets

survival

Circadian clock

metabolic

Gap junction assembly
signaling
* Pathways are up-regulated in both poly(I:C)
and anti-PD-1 treated groups
# Pathways are up-regulated in both anti-PD-1 and
combination poly(I:C)+anti-PD-1 treated groups
+ Pathways are up-regulated in poly(I:C), anti-PD-1, and
combination treated groups
` Normalized enrichment score (NES); up-regulated
pathways defined as (NES) > 0
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muscle differentiation
platelet aggregation,
hemostasis
JNK signaling; stress
response, IRF3, T cell
differentiation and
apoptosis
MAPK signaling in stress
response
CD100 binding
activation, immune
activation by CD72
MAPK signaling, cell
migration, survival,
differentiation

26

1.54

35

1.54

16

1.53

49

1.52

24

1.64/1.63

19

1.6/1.63

30

1.56/1.45

115

1.52/1.45

16

1.71

muscle contraction
cellular response to ER
stress, UPR

46

1.56

41

1.55

collagen formation
extracellular matrix
organization

53

1.54

76

1.54

cell-cell communication
glycosaminoglycan/prote
oglycan; antiinflammatory
proteoglycan; antiinflammatory
proliferation,
differentiation, survival
circadian rhythm,
metabolic pathways

24

1.52

47

1.5

19

1.5

21

1.47

49

1.46

cell-cell communication

16

1.45

proliferation,
differentiation, survival
angiogenesis,
proliferation, migration
maturation of notch
receptor
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Figure 19: Poly(I:C) and anti-PD-1 mAb combination therapy promotes gene
expression associated with survival, metabolism, and Th-1 type anti-tumor
immunity and decreases angiogenesis. A) Heatmap illustrating normalized
(log2) gene expression patterns from MB49 whole tumor lysates treated with
either PBS+IgG Ab, poly(I:C), anti-PD-1 mAb, or poly(I:C)+anti-PD-1 mAb; RNA
was isolated from tumors 17 days post-implantation (4 treatments) (Figure 4A).
Each column represents one mouse. B) Average relative gene expression of
indicated genes associated with effector function, fatty acid oxidative metabolism,
glycolysis, and AKT, MEK/ERK pathway from the 4 treatment arms (n=4 per
group). C) IHC staining for CD31 (PECAM-1) in end point tumors from 38 days
post-implantation (11 treatments); Scale bar = 100µm. Image is representative of
3 tumors per treatment group. D) Quantified microvessel density (MVD)
averaged from IHC CD31-stained tumors (6C) (n=3 per group). All values
normalized by DeSeq and log2 transformed (heatmap). Error bars indicate mean
± SEM, n=4 per group. *p<0.05, **p<0.01 with Student’s t test.
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4.3: Summary and Discussion

IFN-I, while capable of inhibiting tumor growth and inciting an immune
response to aid in host defense, intrinsically increases mechanisms of tumor
resistance by upregulating expression of immune checkpoint markers like PD-L1
on cancer tissue and surrounding cells of the TME. Immune inhibitory
checkpoints are important in regulating autoimmunity and collateral tissue
damage in an immune response, but in the context of cancer, can inhibit effector
T cell responses by inhibiting proliferation and IL-2 secretion and promoting T cell
exhaustion and anergy (257). Despite these mechanisms of adaptive immune
resistance, therapeutic antibody-mediated blockade of inhibitory checkpoints has
produced tumor regression and durable patient responses (415). Because of the
inherent PD-1/PD-L1 pathway tumor evasion strategy induced by IFN treatment,
I explored the potential of IFN-I therapy combined with PD-1pathway checkpoint
inhibition to provide synergistic treatment benefit to MB49 tumors.
In this chapter, I show that combination IFN-I and anti-PD-1 mAb
checkpoint blockade reduces tumor burden and significantly prolongs survival,
though there is no significant difference in tumor reduction between poly(I:C)
alone and combination treatment. Similarly, there were no significant differences
in the frequencies of CD8, CD4, NK, Ly6G, or Ly6Chi cells between poly(I:C),
anti-PD-1, or combination treatment, although there was an increasing trend in
Ly6G cells with corresponding decrease in Ly6Chi cells with combination therapy
that was consistently reproducible. Molecular profiling of the differently treated
tumors revealed that poly(I:C), anti-PD-1, and combination treatment all
increased expression of genes related to antiviral response, interferon, and
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cytokine signaling, and decreased genes related to angiogenesis and
vascularization (CD31 IHC). Interestingly combination treatment enriched gene
signatures related to ECM organization and collagen formation, possibly alluding
to an increased stromal infiltrate. Further clarification of which GSEA analyzed
pathways are conserved or different between each treatment group is described
in Figure 20A. I also compared the molecular changes seen in PBS-, poly(I:C)-,
anti-PD-1 mAb-, and combination-treated MB49 tumors to pre- and post- AdIFN treated patient tumor samples (from Figure 6). I found that signaling
pathway genes, such as IFN response and cytotoxicity related CXCL9, CXCL10,
TRAIL, CCL2, CCL5, CD8, and PRF1 are similarly upregulated in poly(I:C)-, antiPD-1 mAb-, and combination-treated MB49 tumors, like in the post-Ad-IFN
specimens; however, metabolic pathway genes such as FASN, ACLY, and
ACACA, are only similarly downregulated with single agent poly(I:C)/IFN-I
treatment, not with anti-PD-1 or combination treatments.
My initial hypothesis that combined usage of IFN-I therapy with anti-PD-1
checkpoint blockade would synergize to provide greater clinical benefit was not
herein definitively proven. While I did see a difference in animal survival, there
were no clear factors as to how combination therapy provides greater clinical
benefit, based on lack of significant differences in tumor burden, no major
differences in the tumor-immune infiltrate, and RNA sequencing analysis shows
stronger upregulation of IFN response and immune cytotoxicity genes in poly(I:C)
alone than other treatment groups. Overstimulation of inflammatory pathways
has been shown to produce a “cytokine storm” that can result in significant
pathology and ultimately death (457, 458). In a model of viral infection and
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Figure 20: Summary: Gene expression pathways regulated by single and
combination treatment of MB49 tumors. A) Enriched signaling pathways
identified by GSEA analysis in MB49 tumors treated with either poly(I:C), antiPD-1 mAb, or poly(I:C)+anti-PD-1 compared to PBS/IgG control. B) Canonical
pathways upregulated or downregulated in poly(I:C) and poly(I:C)+anti-PD-1
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mAb treated tumors identified by IPA analysis. ISGs, interferon sensing genes;
PDGF, platelet derived growth factor; LXR/RXR, liver X receptor/retinoid X
receptor; PRRs, pattern recognition receptor; IRF, interferon regulatory factor;
THOP, thimet oligopeptidase; GPCR, g protein coupled receptor; MMPs, matrix
metalloproteinases.
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poly(I:C), mice lacking an adaptive immune response (nude and Rag-/- mice)
had higher mortality rates after virus/poly(I:C) dosage due to higher abundances
of proinflammatory cytokines TNF and IFNγ in the serum days after infection
compared to WT mice (459). Addition of T cells to the non-T cell, TLR3stimulated system efficiently prevented this cytokine surge, suggesting that active
T cell monitoring is necessary to temper an innate response. One hypothesis for
why combination treated mice had improved survival over poly(I:C) alone is that
the addition of anti-PD-1 mAb is able to reactivate T cells (particularly Tregs) that
have become exhausted from IFN-I stimulated PD-L1 expression, which results
in tempering of the innate cytokine response invoked by IFN-I signaling. This
warrants future analysis in the MB49 model.
GSEA and RNAseq analysis of MB49 tumors treated with either single
agent poly(I:C), anti-PD-1 mAb alone, or combination therapy showed anticipated
enrichment in genes and pathways related to IFN induction, viral stress
response, cytokine production and innate immune activation, as well as MAPK
and ERK signaling in comparison to PBS treated control tumors. MAPK/ERK
signaling traditionally is associated with cell survival, proliferation, and
differentiation. However, there is evidence that ERK signaling has pro-apoptotic
functions in response to damage stimuli (460), and this mechanism may add to
the immune component of the IFN-I anti-tumor response, providing further
survival benefit demonstrated in this study.
Previously published studies identified that blockade of the PD-1/PD-L1
axis reverses T cell exhaustion, re-inducing glycolysis and anabolic metabolism
to produce a more active state (317, 461). In this work, I found that poly(I:C),
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anti-PD-1 mAb, and combination treated groups have increased levels of
enzymes involved in glycolysis and the TCA cycle (GLUT1, HCK, GCK).
Interestingly, I also found in comparison to poly(I:C) treatment alone, the addition
of anti-PD-1 mAb enriched for extracellular matrix reorganization, collagen
formation, and increased genes related to FAO and fatty acid synthesis such as
FASN, ACLY, and ACACA. Increasing mitochondrial FAO metabolism in T cells
has been shown to favor the formation of long-lived memory T cells (462, 463).
However, the whole tumor RNA analyzed here is likely more reflective of the
tumor genome than the immune microenvironment. Since and fatty acid
synthesis and glycolysis are necessary for cellular growth and proliferation (464),
this analysis suggests that combination treated tumors are upregulating
pathways of proliferation in the tumor cells while simultaneously inhibiting tumor
growth. Upregulation of expression of genes involved in ECM remodeling and
mesenchymal transition has been shown to be a marker of resistance to anti-PD1 therapy (innate anti-PD-1 resistance, IPRES) (465). The possibility of
combination therapy upregulating mechanisms of resistance pathways will need
to be further explored in the MB49 model.
Despite no clear synergistic benefit from combination therapy, and no
definitive reasoning as to why combination treatment prolongs animal survival, I
have hypothesized that addition of anti-PD-1 antibody may contribute to
activation of regulatory immune function to subdue chronic inflammation adverse
effects, which may improve survival. I have also suggested that “rescue” of fatty
acid synthesis and metabolic gene expression by addition of andti-PD-1 mAb
may contribute to the differences seen between combination treatment and
poly(I:C) alone. Ingenuity Pathway Analysis (IPA) canonical pathway analysis
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also shows that upregulated pathways are predominantly immune response
related in poly(I:C) treatment, whereas combination treatment upregulates
calcium signaling, G-protein signaling that regulates metabolic enzymes, ion
channels, and transcriptional machinery, matrix metalloproteases, and wound
healing pathways (actin cytoskeleton and intrinsic prothrombin activation
pathways) in addition to immune response pathways and leukocyte extravasation
signaling (Figure 20B). Combination treatment also more dramatically
downregulates upstream regulator ACKR2, involved in regulating inflammatory
cytokines. This combination of immune response, metabolic pathways, and ECM
modification may be related to greater immune infiltration, or to promoting cancer
growth and metastasis. Immune checkpoint inhibitors can regulate T cell
migration, and particularly in the case of CTLA-4, can increase immune cell
infiltration into tumors (and other tissues) (466). PD-L1 has been found to localize
to the central T cell activation cluster and decrease antiviral CD8 T-cell motility;
antibodies to PD-1 and PD-L1 restored CD8 T cell motility by limiting interaction
time between T cells and DCs (467). While increasing motility, this effect of PD-1
blockade becomes complicated as it reduces the efficacy of TCR signaling,
raising the threshold needed for T cell activation (466). These analyses
demonstrate that while not clearly synergistic, anti-PD-1 mAb in addition to IFN
therapy may provide clinical benefit by increasing immune and TME regulatory
functions that are not stimulated by IFN-I activation alone. Thus, though not
synergistic in these studies, combination treatment of IFN and immune
checkpoint blockade may provide improved therapeutic outcomes in NMIBC
patients.
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Chapter 5: Global Discussion (Implications) and Future Directions

Bladder cancer is a heterogeneous disease that affects a large proportion
of cancer incidences, particularly in men, each year. Most patients are diagnosed
with NMIBC, and though this classification of the disease is less severe and lifethreatening compared to MIBC, current standard treatment practices are not welldefined, and result in 30-40% of patients exhibiting recurrent and progressive
tumors (55, 69). Therefore, finding an effective alternative therapy that is
mechanistically understood is essential to improve patient outcomes. Use of type
I IFN and adenoviral-mediated IFN (Ad-IFN) have shown clinical response in
this patient population, however i) its mechanisms of action have not been well
characterized, and ii) IFN-I has been shown to increase tumor and TME immuneevasion strategies such as upregulation of checkpoint markers, prompting the
need to develop potential combination therapies. In this dissertation, I tested the
hypothesis that immune-mediated mechanisms of type I IFN therapy with the
general hypothesis that localized IFN-I treatment would increase immune cell
recruitment and activation in tumors, creating an IFN driven antitumor response
and an environment in which checkpoint blockade immunotherapy could
counteract immune evasion and T cell exhaustion. In the course of these studies,
I learned that local delivery of poly(I:C) and viral-mediated IFN incites
inflammatory cytokines and chemokines, increases intratumoral effector immune
cells, and inhibits tumor growth, prolonging survival. In characterizing this
response, I found IL-6 had an important role in regulating positive responses to
type I IFN therapy in both mice and humans, that IL-6 signaling was necessary
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for antitumor effects of Ly6G cells and NK cell and T cell proliferation and
activation. I further established that local delivery of poly(I:C) in combination with
anti-PD-1 checkpoint modulator prolongs survival, which may be a product of
anti-PD-1 mAb’s ability to regulate TME cell metabolism, and to reactivate
regulatory cells to balance treatment efficacy and inflammatory pathology. I
touched on how my findings supported or contradicted the current knowledge in
the field, and speculated on the potential underlying mechanism for my results. In
this chapter, I will discuss the potential future implications of my work, and
address what areas of study need to be further pursued.
IL-6 signaling has been portrayed as both promoting oncogenesis by
supporting cancer cell proliferation, survival, and metastasis, and opposing tumor
growth by mobilizing immune responses against the tumor. My findings outlined
in Chapter 3 indicate that contrary to many publications categorizing high IL-6
levels as a marker for poor prognosis and tumor progression, the induction of IL6 in mice and patients with bladder cancer treated with IFN therapy correlated
with antitumor response and tumor regression. This implies that measureable IL6 levels may be used as a positive prognostic marker for IFN treatment of
bladder cancer in the future. In this dissertation, I only touched on the need of IL6 in the poly(I:C) antitumor response, inhibiting tumor growth, promoting NK and
T cell activation, and increasing intratumoral Ly6G+ cells, but further analysis of
IL-6’s mechanisms of action would aid in understanding it’s defined role in the
antitumor response for bladder cancer. IL-6 has been shown to inhibit Treg
suppression of DC-mediated T cell activation (468), and promote Th17 cell
differentiation, a process often connected by IL-6’s ability to suppress the Foxp3dependent Treg developmental program in favor of Th17 formation in the
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presence of TGF (469). The effect of IL-6 on the CD4 T cell compartment in
MB49 and other bladder cancer models needs to be further pursued as another
effector mechanism of IFN-I.
One of the areas brought into question from my studies was how
combination treatment increased survival without having significantly smaller
tumor sizes or greater expression of immune effector gene expression than
poly(I:C) alone. To better elucidate the objective differences, if there are any,
between poly(I:C) and combination poly(I:C) + anti-PD-1 therapy, the treatment
dosing schedule may be an important area of future research. In this study, I
treated mice concurrently with IFN agonist poly(I:C) and PD-1 inhibitor based on
previously published work (375), however a delayed application of anti-PD-1,
after IFN-I has been able to incite the inflammatory response (and upregulate
PD-L1) may provide greater benefit. It has been shown that chemotherapy and
radiation therapy given prior to checkpoint inhibition therapy generate antitumor
and abscopal responses (470). As these therapies act to stimulate the antitumor
response by increasing tumor antigenicity and immune cell activation, the same
reasoning can be applied to innate immune stimulating therapy (IFN) being given
prior to inhibitory checkpoint antagonists.
Additionally, in the RNAseq data (Figure 19), I show that in comparison to
poly(I:C), combination treated tumors have enriched expression of fatty acid
metabolism. In Chapter 4, I mentioned that increasing mitochondrial FAO
metabolism in T cells has been shown to favor the formation of long-lived
memory T cells (462, 463), and FAO is necessary for other effector immune cell
function: TLR-stimulated macrophages require increased FAO, and specifically
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ACLY function, for cancer cell phagocytosis and antitumor activity (471).
However, bladder cancer has been known to rely on glycolysis as well as fatty
acid synthesis for oncogenesis (430, 431), and so, dual expression of fatty acid
metabolism and glycolysis from the RNAseq analysis may indicate that the tumor
itself is proliferating and may be a sign of tumor progression and therapeutic
resistance.
For the tumor to overcome an antitumor defense, it must co-opt the TME
and induce its polarization to a more pro-tumor, immunosuppressive immune cell
phenotype, thereby encouraging tumor growth and survival. Specific identification
of which cells (immune subtypes or tumor) are exhibiting increased fatty acid
metabolism (as well as glycolysis) is therefore an important next step in
determining therapeutic strategies for bladder cancer. If the immune cells are
exhibiting glycolysis and FAO metabolic signatures, this would signify an
activated immune response capable of attacking tumors. If the tumor cells show
increased glycolysis and FAO, this may be a sign of the Warburg effect,
increased nucleotide, amino acid, and lipid biosynthesis, and ultimately tumor cell
proliferation (472). To differentiate metabolic signatures between pro-tumor and
anti-tumor immune cells, Liu and colleagues tested preferred utilization of TCA
cycle intermediates for M2 pro-tumor macrophages and TLR-stimulated antitumor macrophages. M2 macrophages preferred the use of exogenous fatty
acids for TCA cycle components (and increased lipid transporter expression),
whereas TLR stimulated macrophages showed preference for de novo lipid
synthesis, displaying a shift away from complete utilization of carbon from
glucose towards glutamine anaplerosis for generating TCA cycle components
(471). A similar strategy can be employed to better understand the mixed
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metabolic RNA profile seen in the treated MB49 tumors: investigation into ECAR,
OCR, and lipid synthesis analysis of intratumoral immune cells and tumor cells
will be important for identifying which cell components the metabolic changes are
specifically attributed to and can help identify cells that are immunosuppressive,
aiding in pinpointing targets for therapeutic intervention.
Combination treatment also showed enrichment of ECM and collagen
modification gene expression, potentially hinting at increased cell motility or
proliferation. Similar to the uncertain attribution of glycolysis and FAO metabolic
genes, which cells contribute to this increased expression remains unclear. As
previously stated, upregulation of expression of genes involved in ECM
remodeling and mesenchymal transition has been shown to be a marker of tumor
resistance to anti-PD-1 therapy in patients with metastatic melanoma (465).
Further investigation into anti-PD-1 therapy resistance mechanisms in bladder
cancer, and other cancers is an important field to pursue, and has only begun to
be understood at the innate and adaptive cellular level (473). It is not currently
clear if the increased expression of cell motility and ECM modulation signaling is
related to PD-1 resistance in the MB49 model. However, to investigate PD-1
resistance as a possibility in IFN+anti-PD-1 treatment of bladder cancer,
carcinogen-induced or transgenic murine models of bladder cancer may provide
the best tumor genesis rate to test combination therapy resistance mechanisms,
as MB49 tumors are fast-growing and may not provide sufficient time and
opportunity to study.
Looking to the future of bladder cancer treatment and considering my
findings in this dissertation, I believe that efforts to inhibit IL-6 signaling, because
of its role in chronic inflammation and potential relationship with tumor promotion,
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are hasty (474). In models which require T cell priming for activation, IL6-/- mice
display impaired involvement of innate cells (475). Likewise, inhibition of
downstream IL-6-target STAT3, because of its role in regulating cell survival,
proliferation, and angiogenesis (476), could negatively preclude the immune
response due to STAT3 regulation of granulopoiesis, DC development and
function, T cell differentiation and function, Treg development, and antiinflammatory signaling, among other effects (477). In this work, I show that IL-6 is
a necessary component in the IFN-driven antitumor response. Immunotherapy,
radiation therapy, and chemotherapy all rely on the immune response, including
IFN signaling, to combat tumor growth; consequently, to some degree this will
rely on inflammatory cytokines such as IL-6 to potentiate the antitumor immune
response. Therefore, focus should be directed towards inciting the immune
response in bladder cancer treatment, not inhibiting its effector branches. AdIFN therapy theoretically reaches the goal of activating the immune response.
The use of a viral vector delivery system can be difficult in cancer types that are
systemic (blood), or those hard to reach without systemic administration
(pancreatic, colon, lung, some prostate, etc.), exhibiting potential bystander
events and adverse effects; this same reasoning makes viral-mediated therapy in
bladder cancer more advantageous because of the ability to locally deliver the
drug and avoid systemic toxicities. Because melanoma and other skin cancers
are also easily accessible, Ad-IFN may be utilized in these indications as well.
Despite the advantage of local delivery, treatment with Ad-IFN still shows
less than 50% response rates in NMIBC patients (66, 67). This may be due to
mixed ability of the drug to permeate through different patient’s urothelial barrier,
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the heterogeneity of the bladder tumor landscape, upregulated immune evasion
mechanisms, and inaccurately staged and stratified disease, as previously
discussed. However, for BCG unresponsive patients, I think Ad-IFN is still a
promising therapeutic alternative to cystectomy because it can sustain patient
quality of life, and the contributing reasons for resistance to IFN therapy can be
addressed by more vigilant clinical assessment and combination therapeutic
approaches to target immune evasion strategies such as inhibitory checkpoints.
To this end, PD-1 inhibition in combination with IFN therapy may not be
the best therapeutic option when considering a more holistic immune therapy
approach to bladder cancer. PD-1/PD-L1 pathway inhibition is effective at restimulating exhausted T cells already in the tumor, whereas CTLA-4 inhibition
has actually been shown to increase T cell activation and chemotaxis to tumors
(294). The potential combination of anti-CTLA-4 mAb with viral-mediated IFN
may prove to be more successful in inhibiting UC tumor growth though the
enhanced recruitment of effector T cells, an additive effect to IFN-I’s diverse
antitumor mechanisms. Anti-CTLA-4 therapy has been helpful to disease
phenotypes with high mutational loads, due to more probable neoantigen targets
for T cell attack (90); thus bladder cancer, having the third highest mutation
landscape after melanoma and lung cancers (478), is a prime candidate for
CTLA-4 targeted therapy. Focusing more on therapies that are already approved
for use in bladder cancer, and have shown efficacy, the combined use of IFN
with BCG may be an attractive treatment strategy. Combination BCG + IFN2b
was shown to potentiate the effects of BCG alone with a response rate of about
60% in prior BCG failed patients (479). Because this study was performed with a
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recombinant IFN protein, I would speculate that viral-mediated IFN would provide
even greater clinical benefit due to its enhanced durability and permeation into
the bladder wall.
Together, my results provide a preclinical conceptual example for using
type I IFN activation to increase the therapeutic benefit of PD-1 blockade for
bladder cancer patients, as well as a rationale for pursuing further studies in
NMIBC to optimize a treatment protocol (dosing and timing). Recent US Food
and Drug Administration approval of atezolizumab (anti-PD-L1 mAb) and
nivolumab (anti-PD-1 mAb) for treatment of metastatic urothelial carcinoma (63)
has brought into question the role of immune therapy earlier in the treatment of
UC, and thus clinical trials examining the effect of checkpoint inhibitors in earlier
staged cancer is ongoing. To this point, Pietzak and colleagues showed that
chemotherapeutic treatment of “secondary” MIBC, that is, tumors that have
progressed to higher staged MIBC from previously diagnosed and treated
NMIBC, had lower response rates and short survival compared to “primary” de
novo, treatment naïve MIBC (480). Moving forward, I think the bladder cancer
treatment field should focus on implementing a combination innate and adaptive
stimulating immunotherapy strategy at earlier disease stages (not just BCG failed
patients). It can broadly affect more patients rather than personalized targeted
molecular therapies, and lead to better clinical outcomes for many subtypes of
bladder cancer patients.
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Chapter 6: Methodology

Patient Samples
Patient specimens utilized in this study were collected from previous
Phase I, Phase Ib, and Phase II clinical trials with adenoviral interferon-α2b
formulated with Syn3 (Ad-IFNα/Syn3) with patient eligibility, treatment, and
specimen collection approved by the University of Texas MD Anderson Cancer
Center institutional review board (IRB) (66, 67, 408).
Urine samples utilized for preliminary marker identification (Figure 7) were
collected for clinical research use from informed and consented patients about to
undergo standard TURBT. Specimen collection was approved by the University
of Texas MD Anderson Cancer Center IRB.

Mice
Wild-type male C57BL/6J mice, IL-6KO mice, RAG-/-, and p53 +/- mice
were purchased from The Jackson Laboratory (Bar Harbor, ME). All genedeficient mice used are on the C57BL/6 background. IFNAR-/- (481) were
provided by Dr. Paul W. Dempsey (Department Of Microbiology and Molecular
Genetics, University of California, Los Angeles) and Dr. Tadatsugu Taniguchi
(Department of Immunology, Tokyo University, Japan) to Dr. W. Overwijk and
crossed to the C56BL/6 background. IL15Rα-/- mice (482) were originally
generated by and obtained from Dr. Averil Ma through Dr. Leo Lefrancois and
crossed to the C57BL/6 background. All animal experiments were performed
according to the institutional guidelines for the care and use of laboratory
animals.
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Cell Lines and Treatment in vitro
MB49-GFP/luciferase murine bladder cancer cells were generously
donated by Dr. Robert Svatek (the University of Texas Health San Antonio). Cells
were grown in culture in modified Eagle medium containing 10% fetal bovine
serum and 1% penicillin/streptomycin. MB49 bladder cancer cells were seeded in
6-well plates and treated with 0-10,000 IU/mL recombinant murine IFNα (PBL
Assay Science, Piscataway, NJ). After 24 hours of stimulation, cell death and
apoptosis were analyzed by a combined PI/Annexin V (APC) assay (Invitrogen
[Thermo Fisher Scientific], Carlsbad, CA), and analyzed by flow cytometry
whereby early apoptosis (Annexin+PI-) and late apoptosis (Annexin+PI+) were
quantified (n=2 biological replicates). UPPL1541 and UPPL1595 cell lines are
established from a spontaneous primary bladder tumor in an Uroplakin-Cre
driven PTEN/P53 knockout genetically engineered mouse model and were
generously provided by Dr. William Kim (UNC Chapel Hill).

Tumor Transplantation
Mice were injected subcutaneously into the right flank with 1×10 5 MB49
bladder cancer cells (1×106 or 1×107 for UPPL1595 and UPPL1541,
respectively). For analysis of abscopal effect, following primary tumor injection of
MB49 on right flank, a secondary tumor (1×105 MB49 cells) was injected in the
left flank 4 days later. Tumor development was monitored by palpation and
fluorescent imaging with the IVIS Spectrum In Vivo Imaging System and Living
Image software (PerkinElmer, Waltham, MA). Mice were randomized into
treatment groups on the basis of fluorescent intensity and palpated tumor size at
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day 6 after implantation. From day 6 on, tumor size was measured every 3 days
by caliper and was recorded as Area [L × W] in millimeters. Mice with tumors
exceeding 20 mm in diameter or with large ulcerations were deemed moribund
and euthanized. Each point on tumor growth graphs reflects the average area of
the total starting number of mice per treatment group; graph lines are stopped
when multiple mice in a group are euthanized. Experiments were performed in
groups of five or more mice and repeated at least twice.

Treatment of Mouse Tumors and Depletions
When transplanted bladder tumors became palpable, poly(I:C) (100 µg;
Invivogen, San Diego, CA) was injected peritumorally beginning on Day 6 or 7
and continued every 3 days until mice were deemed moribund, or for tumor
analysis after a total of 2, 3, or 4 treatments as denoted in Figure 8, 17.
Therapeutic blockade of PD-1 was performed using rat anti-mouse PD-1 mAb
(200 µg, i.p., clone RMP1-14; BioXcell, West Lebanon, NH) or control-rat IgG
mAb (200 µg, i.p.; Jackson ImmunoResearch Laboratories Inc., West Grove, PA)
every 3 days in conjunction with poly(I:C) treatment. Antibody-mediated depletion
of T cells or natural killer cells was induced with rat anti-mouse Thy1.2 mAB (300
µg, i.p. clone 30H12; BioXcell), rat anti-mouse CD8 mAb (300µg, i.p. clone 2.43;
BioXcell), or rat anti-mouse Nk1.1 mAb (300µg, i.p. clone PH136; BioXcell)
delivered two times, 1 week apart. Ly6G and CSFR1 mAbs (400µg, i.p. clones
1A8 and AFS98 respectively; BioXcell) were given three times a week until
mouse morbidity. Greater than 85% depletions of target cells were confirmed by
flow cytometry of peripheral blood samples taken 1-2 days after Ab treatment.
Efficiency of cell depletions is represented in Figure 21. All treatments and
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Figure 21: Efficacy of Immune cell subset depletions. A) mAb depletion of
Ly6G+ cells; flow plot is of gated lineage-(TCRβ-CD19-NK1.1-)CD11b+ cells. B)
mAb depletion of CD8 T cells; flow plot is of gated TCRβ+ cells. C) mAb depletion
of NK cells; flow plot is of gated TCRβ- cells. D) mAb depletion of all T cell
subsets by Thy1.2 antibody. All samples from peripheral blood. Plots are
representative of n=5.
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depletions were performed in Wild-type male C57BL/6J mice, male IL-6KO mice
(B6.129S2-Il6tm1Kopf/J), and male RAG-/- (B6.129S7-Rag1tm1Mom/J) mice (The
Jackson Laboratory; Bar Harbor, ME).
p53+/- mice (8 weeks old) were treated with 0.25% N-butyl-N-(4hydroxybutyl) nitrosamine (BBN) in drinking water for 12 weeks (483). By 16
weeks mice develop carcinoma-in-situ (CIS) which proceeded to invasive cancer
by 30 weeks. Mice were treated with LV Ctrl or LV IFN (3X107 virus particles) for
4 weeks starting at 16 weeks of age (Lentiviral Vectors [LV-Control and LV-IFN]
provided by FKD Therapies, University of Finland). Excipient SYN3 (1mg/ml) was
used as vehicle for all treatment. For intravesical treatment, mice were
anesthetized and mouse urethra was catheterized with 20G angiocatheter and
after emptying the bladder contents, virus was instilled (100 μl) volume and
allowed to dwell in the bladder for 40 mins. After instillation of virus, mice were
allowed to recover and returned to their cages.

T cell Stimulation
For intracellular cytokine and IFNγ staining, MB49 tumor-infiltrating
immune cells were isolated by manual homogenization followed by Percoll
gradient, and plated into 6-well plates coated with anti-CD3 antibody, incubated
in RPMI with 10% fetal bovine serum with protein transport inhibitors GolgiStop
and GolgiPlug (2 µg/mL; BD Biosciences, San Jose, CA) for 5 hours (n=4). After
incubation, cells were stained for surface markers and then fixed and
permeabilized prior to staining for intracellular proteins.

Murine Cytokine Analysis
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Murine cytokines were measured by ELISA: IFNα (PBL VeriKine Mouse
Interferon Alpha ELISA kit, 42120-1; Piscataway, NJ) and IL-6 (R&D Mouse IL-6
Quantikine ELISA Kit, M6000B; Minneapolis, MN). Samples were run in duplicate
and ELISA was performed according to manufacturer instructions. Plates were
read on Molecular Devices Spectra Max Plus384 plate reader.

Immunohistochemistry and Immunofluorescence Staining
Mouse tumors were fixed in 10% phosphate-buffered formalin, embedded
in paraffin, and sectioned by the Research Histology Core Laboratory at The
University of Texas MD Anderson Cancer Center. Patient tumors were isolated
and processed according to the phase I trial protocol (66, 408) and obtained from
MD Anderson. Immunohistochemistry was performed with either rat anti-mouse
CD31 mAb (SZ31, Dianova, Hamburg, Germany) or rabbit anti-human CD3 pAb
(A0452, Dako [Agilent], Santa Clara, CA) followed by rabbit-anti rat HRP- or
goat-anti rabbit HRP–conjugated secondary antibody respectively (Bio-rad
Laboratories, Hercules, CA) and the DAB peroxidase substrate kit (Vector
Laboratories, Inc. Burlingame, CA). Sections were then counterstained with
hematoxylin. Tissue sections were blindly quantified by manual counting.
Representative areas (2-3) from each CD31 stained section (n=12 in total) with
most intensive microvessel density was captured under the light microscope at
200x (Leica). MVD per tumor section was calculated from the average count of
CD31+ vessels per representative area, averaging total number from n=3 tumors
per treatment group. Total image length is 384µm. Immunofluorescence was
performed using rat mAb CD4 (GK1.5, Abcam, Cambridge, MA) and rabbit pAb
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CD8 antibodies (ab4055, Abcam). Sections were examined with a Nikon
microscope and camera and processed in ImageJ.

Flow Cytometry
Tumor-infiltrating immune cells were isolated by manual homogenization
and digestion of tumors or bladders (BBN-induced), followed by Percoll gradient,
and stained with fluorochrome-conjugated mAbs specific for mouse surface
markers CD45, CD44, CD8, CD4, Nk1.1, CD11b, CD11c, Ly6C, Ly6G, CD19,
TCRβ, F4/80 (BD Biosciences, Ebioscience/Thermo Fisher Scientific) according
to standard procedures. Intracellular staining (T cell Stimulation) for IFNγ, and
Ki-67 and granzyme-B was performed after permeabilization of cell membranes
using the Transcription Factor Staining Buffer Set from eBioscience
(ThermoFisher).
Human urine samples were collected and stained for immune and
epithelial markers for flow cytometry. Briefly, samples were centrifuged at 2000
RPM, washed with DPBS, and centrifuged at 2000 RPM again. Pellets were
resuspended in 1mL of DPBS, counted on hemocytometer, and aliquoted to a
maximum of 106 cells per tube. Samples were then stained with fluorochromeconjugated mAbs specific for human markers CD45, cytokeratin, CD8, TCR,
PD-1, PD-L1 (Thermo Fisher Scientific) according to standard procedures.
All samples were run on a BD LSRFortessa unit and analyzed by FlowJoX
software (Flowjo LLC, Ashland, OR).

Reverse Transcriptase PCR
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Tumor samples were harvested and immediately snap-frozen in liquid
nitrogen. Total RNA was isolated using the mirVana miRNA isolation kit with
phenol (Ambion [Thermo Fischer Scientific], Carlsbad, CA) with concentration
measured on the NanoDrop ND-1000 Spectrophotometer. One-step quantitative
reverse transcriptase PCR was performed with diluted RNA, AgPath-ID One-step
reverse transcriptase PCR reagents, and Taqman gene expression assay
primers (Thermo Fisher Scientific) for the genes indicated, using relative
expression of GAPDH as a reference gene. Samples were analyzed on the
StepOnePlus Real-Time PCR System with StepOne Software v2.3 (Applied
Biosystems [Thermo Fisher Scientific]).

RNA-seq of Murine Tumors
Stranded Total RNA sequencing was performed by the MD Anderson
Sequencing and Microarray Facility (SMF) on the Illumina Hi-Seq 4000 platform.
RNA samples were isolated from MB49 tumors using the mirVana miRNA
isolation kit with phenol (Ambion [Thermo Fisher Scientific]), confirmed purity and
concentration by the Agilent 2100 Bioanalyzer (Agilent Technologies [Thermo
Fisher Scientific]) and Nanodrop ND-1000 Spectrophotometer, and sent to SMF.
Raw reads in FASTQ format were aligned to the mouse reference genome,
GRCm38/mm10, using MOSAIK alignment software. Mapped reads were used to
generate raw counts for each gene using HTSeq. Counts data were normalized
across samples with DESeq (484) and normalized expression values were
analyzed by Morpheus matrix visualization and analysis software (Broad
Institute), Gene Set Enrichment Analysis (GSEA) software (Broad Institute), and
Ingenuity Pathway Analysis (IPA) software (Qiagen). The up-regulated pathways
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in GSEA were defined by a normalized enrichment score (NES) >0. Only the top
20 pathways more enriched in each treatment group were listed.

Urinary Cytokine Analysis
Frozen patient urines collected from baseline Day 1 (D1) pre-treatment,
and Day 4 and Day 12 (D4, D12) post treatment of Phase I and II clinical trials
with Instiladrin (Ad-IFNα/Syn3) by the SUOCTC working group were thawed and
diluted before analysis with the Bio-Plex ProTM Cytokine, Chemokine, and Growth
Factor Assay Kit (Bio-Rad Laboratories, Inc., Hercules, CA). We utilized antibody
targets from the Human Cytokine Standard Groups I and II. Samples were run in
duplicate and the plate was read with Bio-Plex ManagerTM software (Bio-Rad
Laboratories, Inc) in the MD Anderson Department of Surgery. Observed
concentration was log2 transformed, and graphed with baseline corrected to Day
1 levels of each cytokine. Patients with undetectable levels of cytokines were left
out of analyses. Assessment: of the 39 total patients, 13 were deemed as
“responders” (CR) as defined by no evidence of recurrence of a high grade tumor
by cystoscopy, cytology, or if clinically indicated, biopsy at 12 months. The other
26 patients were deemed “non-responders” (NR). Correlation between IFNa2
levels and other cytokines were deemed as moderately positive if r > 0.5 and
strongly positive if r >0.7. Positive correlation was considered statistically
significant if p value <0.05.

Analyses of Gene Expression for Patients Treated with Ad-IFNα
RNA isolation
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The tumor areas in formalin fixed, paraffin-embedded (FFPE) human
specimens from the Phase I, Ib, and II trials with Instiladrin (Ad-IFNα/Syn3) were
reviewed by a genitourinary pathologist. Total RNA from 8 matched (16 total)
FFPE tumors was isolated using the High Pure miRNA isolation kit (Roche,
Indianapolis, IN) according to the manufacturer’s instructions. Briefly, for the
deparaffinization, five to ten (depending on the tumor area) 10 µm sections were
incubated with xylene for 5 minutes, followed by two ethanol washes and dried
for 10 minutes at 55°C. The dried tissues were incubated with proteinase K for 3
hours at 55°C degree, followed by two washes according to the instructions of
the manufacturer. RNA was eluted with water and treated with DNAse for 30
mins at 37°C. DNAse treated RNA was washed twice according to the with
manufacturer’s instructions and eluted with water. RNA purity and integrity was
measured by NanoDrop ND-1000 and Agilent 2100 Bioanalyzer and only high
quality RNA was used for library preparation.
Library preparation and sequencing
Whole transcriptome RNA sequencing was performed using Ion Torrent’s
AmpliseqRNA platform (Thermo Fisher Scientific) and an Ion Proton sequencer
(Thermo Fisher Scientific). Twenty nanograms of purified RNA was transcribed
into cDNA using the SuperScript® VILO™ kit. Then cDNA was amplified using
the Ion Ampliseq Transcriptome Human Gene Expression Core panel, followed
by ligation of adapters and barcodes to amplicons and purification. Purified
libraries were quantified using the Ion Library Quantification kit (Thermo Fisher
Scientific) according to the manufacturer’s instructions. Libraries were diluted to
100 pM and pooled in sets of 8. Pooled libraries were amplified on Ion SphereTM
particles (ISP) using emulsion PCR and enriched on the IonChef (Thermo Fisher
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Scientific). Template positive ISPs were loaded into Ion PI chips and run on the
Proton instrument in the Genomics Core in the Department of Urology at The
University of Texas MD Anderson Cancer Center.
Bioinformatics Analysis
RNA-Seq gene expression analysis: Primary analysis of RNA sequencing
data was performed using AmpliSeqRNA analysis plugin in the Torrent Suite
Software. This plugin aligned the raw sequence reads to a human reference
genome that contains 20,802 RefSeq transcripts (hg19 Ampliseq
Transcriptome_ERCC_V1.fasta) using the Torrent Mapping Alignment Program
(TMAP). Then, the number of reads mapped per gene will be counted to
generate raw counts files and normalized reads per gene per million mapped
reads (RPM) files. To visualize expression patterns, log ratios of POST/PRE
gene expression of matched tumors were used for hierarchical clustering with
Cluster and TreeView (485), or log2 normalized expression values were analyzed
by Morpheus matrix visualization and analysis software (Broad Institute).
Assessment: of the 8 total patients analyzed, none were classified as
“responders” (CR) as defined by no evidence of recurrence of a high grade tumor
by cystoscopy, cytology, or if clinically indicated, biopsy at 12 months.

Statistical Analyses
Statistical analyses of experimental results were evaluated with the
GraphPad Prism 7 software. Two-tailed Student t tests, log-rank analyses, or
multiple unpaired t tests were performed using averaged treatment group
measurements at any one time point, as indicated. One way ANOVA with
multiple comparisons was used for patient urine samples for each cytokine.
143

Results were considered statistically significant when *, P < 0.05; ** P <0.01; ***
P<0.001.
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